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Thesis Summary 
Early diagnosis of lung cancer improves patient outcomes which has led to a search for non-invasive 
diagnostic tests suitable for population screening. Volatile organic compounds (VOCs) in exhaled 
breath have shown potential, however, confirmation of the metabolic origins and disease specificity of 
candidate markers is required. Cell culture metabolomics can identify disease biomarkers and their 
origins. To date VOC profiles from in vitro cultured cancer cells have little similarity to cancer breath 
VOC profiles. In vivo, cancer cells experience hypoxia whereas in vitro cells are cultured under 
normoxic conditions. Since hypoxia influences cell metabolism, we hypothesize that cancer cells 
cultured under hypoxic conditions will have altered cell metabolism and produce VOC profiles more 
typical of cancer breathe. This study investigates the effect of hypoxia on metabolic reprogramming in 
A549 lung cancer cells cultured under standard normoxic (atmospheric oxygen) or hypoxic (2% 
oxygen) conditions. Results from quantitative RT-PCR demonstrated a significant upregulation in 
hypoxia of the glucose transporter (GLUT1) and the key TCA regulatory gene PDHK1, demonstrating 
that hypoxia plays a pivotal role in regulating metabolism in A549 cells. A ratio-metric assessment of 
Lipid Peroxidation (LPO) and the production of reactive oxygen species (ROS) showed an increase in 
LPO and a slight decrease in the production of ROS in hypoxic cultures, the combined effect of which 
may serve to equip the cells to adapt to and proliferate under low oxygen. Finally, the comparison of 
endogenous VOCs produced by A549 cells under hypoxic and normoxic conditions identified twelve 
VOCs unique to cells grown under hypoxic conditions including n-pentane, a marker of LPO and 
cancer, and 3-methyl hexane, which has been reported as a biomarker of cancer. This data is consistent 
with the hypothesis that a hypoxic tumour microenvironment may influence cell metabolism leading to 
a unique and diagnostic cancer VOC profile.  
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Abstract 
Lung cancer is the leading cause of cancer deaths. Unfortunately, lung cancer is often diagnosed only 
when it becomes symptomatic and is at an advanced stage when few treatment options are available. 
Hence, a diagnostic test suitable for screening widespread populations is required to enable earlier 
diagnosis. Analysis of exhaled breath provides a non-invasive method for early detection of lung cancer. 
Analysis of volatile organic compounds (VOCs) by various mass spectral techniques has identified 
potential biomarkers of disease. Nevertheless, the metabolic origins and the disease specificity of VOCs 
need further elucidation. Cell culture metabolomics can be used as a bottom-up approach to identify 
biomarkers of pathological conditions and can also be used to study the metabolic pathways that 
produce such compounds. This review summarizes the current knowledge of lung cancer biomarkers in 
exhaled breath and emphasizes the critical role of cell culture conditions in determining the VOCs 
produced in-vitro. Hypoxic culture conditions more closely mimic the conditions of cancer cell growth 
in vivo. We propose that since hypoxia influences cell metabolism and so potentially the VOCs that the 
cancer cells produce then cell culture metabolomics projects should consider culturing cancer cells in 
hypoxic conditions. 
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Introduction 
Lung cancer is one of the five most commonly diagnosed cancers and is the leading cause of cancer-
related deaths throughout the world [1-4].  The five-year survival rate for lung cancer patients is poor, 
largely due to symptoms of lung cancer usually becoming apparent only once the disease has reached 
an advanced stage. Methods for detection of lung cancer are generally invasive and not suited to 
widespread population screening; hence there is a need for a non-invasive, accurate and rapid screening 
test for early detection.  
The exhaled breath of lung cancer patients contains volatile organic compounds (VOCs), some of which 
may be useful biomarkers of the disease. These may provide a non-invasive means to screen for lung 
cancer using techniques such as gas chromatography-mass spectrometry (GC-MS). Previous results 
indicate that lung cancer can be diagnosed in this way with some accuracy [5-29].  The diagnostic VOCs 
identified in these studies were mostly alkanes. However, most lung cancer VOCs that have been 
reported are not disease specific and their metabolic origins remain unknown. Knowledge of all the 
VOCs produced by lung cancer cells should lead to a panel of diagnostic biochemical markers that can 
be measured in combination to increase the sensitivity and specificity of lung cancer diagnosis. 
The use of cell culture metabolomics allows for both the discovery of novel biomarkers of pathological 
conditions and investigation of the metabolic pathways that produce them. However, previous studies 
have found poor correlations between the VOCs from cancer cells in culture and those found by breath 
analysis (see section 2 of this review). We propose that one reason for this discrepancy is the use of 
normoxic in-vitro culture conditions that have traditionally been used for growing cancer cell lines. In 
vivo cancer cells experience low oxygen or hypoxic conditions as a consequence of the diffusion limit 
of oxygen within tissues, which has been measured to be around 150m [30, 31]. Consequently, once 
a tumour grows to greater than 300 m diameter or approximately 15 to 20 cells across, the cells in the 
centre will be experiencing hypoxic conditions. VOCs however are generally hydrophobic and therefore 
lipid soluble and so should pass freely from hypoxic regions of the tumour to enter the circulation to 
travel to the lungs for release by breath. There have been several excellent recent reviews of the VOCs 
associated with lung cancer [32, 33]. In this chapter, I review the current state of knowledge about 
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biomarkers of lung cancer in exhaled breath but with an emphasis on the critical role of cell culture 
conditions in in-vitro studies in determining the VOCs produced.  
Breath Analysis  
Pros and Cons of Breath Analysis  
Breath analysis provides a non-invasive window to observe biochemical processes of the body [34]. 
Ancient physicians knew that the smell of human breath can indicate a certain disease state which could 
be a useful diagnostic tool. For example, diabetes is associated with the sweet smell of acetone in breath, 
renal failure results in a urine-like smell and fishy odour in breath is linked to liver disease [35] (for 
review see Table 1.1 [36]). 
Table 1.1 : Volatile compounds associated with disease 
Volatile compound(s)  Disorder(s)  
Ethane and pentane Oxidative Stress 
Methylated Hydrocarbons Lung or Breast Cancer 
Isoprene Cholesterol metabolism 
Acetone Diabetes Mellitus, ketonemia 
Dimethylsulfide, methyl mercaptane, ethyl mercaptane Liver damage  
Ammonia, dimethylamine, trimethylamine Uremia, Renal damage  
 
Analysis of exhaled breath has many advantages compared to other diagnostic techniques such as 
bronchoscopy or medical imaging. It is non-invasive and painless and exhaled air can be sampled as 
often as necessary without restriction; particularly important for the critically ill and for large scale 
screening in healthy populations for cancer and various other diseases such as renal and liver diseases.  
Currently, clinically available breath tests include: Breath-alcohol test which determines ethanol 
concentration [37], the nitric oxide (NO) test to detect asthma, and diagnosis of Helicobacter pylori 
infection by 13C-urea or ammonia breath tests [38].  
Water soluble and non-volatile chemicals in exhaled breath tend to condense with the water vapour 
whereas VOCs tend to remain in the gas phase. Quantitative analysis of breath condensate is hampered 
by a number of problems including the unclear relationship between assumed alveolar or airway 
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concentrations and substance concentrations in the condensate [39] and the limited stability of some 
compounds. In contrast the kinetics of VOCs can be approximated according to substance solubilities 
and most exhaled VOCs are stable [34]. Consequently, targeting the volatile component of breath for 
analysis reduces many issues associated with analysis of breath condensate.  
VOCs are only a small fraction of the total chemical compounds present in human breath and occur in 
low concentrations in the nmol/L – p/mol/L range [34, 40]. Despite this, in 1971 Pauling et al. detected 
the presence of large numbers of VOCs using microanalysis of breath by newly developed capillary 
Gas Chromatography (GC) [41]. To date, there are more than 800 VOCs detected in the exhaled breath 
in picomolar concentrations [19, 42] and there have been many studies that aim to correlate single 
substances or sets of exhaled markers with clinical conditions [43-47].  
The basic research in breath analysis relies on the advances of analytical technology to detect and 
identify the VOCs. The sample of exhaled breath is analysed using various high-performance equipment 
such as Gas Chromatography Mass Spectrometry (GC-MS), selected Ion-Flow Tube Mass 
Spectrometry (SIFT-MS), Ion-Mobility Spectrometry (IMS) and Proton Transfer Mass Spectrometry 
(PTR-MS). Though GCMS remains a gold standard to perform qualitative and quantitative analysis of 
trace compounds, it is not currently a portable device and also requires trained personnel to operate and 
interpret the data [48, 49]. On the other hand, real time analysis with absolute quantification of VOCs 
can be performed using SIFT-MS but it is both expensive and not ideal for broad profiling [50, 51].  
Although high specificity can be achieved using PTR-MS and IMS, there is a high risk of signal 
interference [52-55]. 
These analytical methods are potentially useful, but not well suited to point of care diagnostics in 
clinical practice. However portable analytical devices are being developed using Field Asymmetric Ion-
Mobility Spectrometer or FAIMS technology and Aspiration Ion-Mobility Spectrometry or AIMS [56]. 
Arasaradnam et al have found that FAIMS technology can be used to differentiate between patients 
with colorectal cancer and healthy controls with 80% sensitivity and 60% specificity [57]. Also, 
standardisation of protocols for collection and analysis of exhaled breath must occur in order to achieve 
consistency in VOC profile analysis [58-60]. 
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Biological Origins of VOCs 
Breath VOCs may be endogenous (generated within the body) or exogenous (absorbed as contaminants 
from the environment). The origins of many endogenous VOCs have now been identified through an 
improved understanding of the mechanisms and kinetics of their synthesis [5] (and for review see [32]) 
(Table 1.2). Alkanes and methylated alkanes in breath are markers of oxidative stress [61-67], which 
are the products from the reaction of lipids with reactive oxygen species (ROS). ROS comprise of 
oxygen free radicals and hydrogen peroxide and are constantly produced in the mitochondria from 
where they can leak into the cytoplasm [62]. Cellular anti-oxidant defences such as glutathione (in 
reduced form) usually protect cells from ROS, but when these defences are insufficient, ROS causes 
peroxidative damage to proteins, polyunsaturated fatty acids, and DNA [64]. These peroxidative 
changes to DNA bases may be carcinogenic [68, 69]. Considerable evidence supports the hypothesis 
that oxidative stress appears to be increased in some cancers [63] including lung cancer [19]. 
Table 1.2: VOCs – Biological Origin 
 VOCs Biological Basis 
Acetaldehyde Ethanol metabolism [70, 71] 
Acetone Decarboxylation of acetoacetate and acetyl-CoA 
Ethane & Pentane Lipid Peroxidation[34] 
Ethylene Lipid Peroxidation [72] 
Hydrogen & Methane Gut Bacteria [73] 
Isoprene Cholesterol biosynthesis [74] 
Methylamine Protein metabolism [72]  
 
Breath methyl alkanes are products of lipid peroxidation of polyunsaturated fatty acids in cell 
membranes, a process that also generates alkanes such as ethane and pentane that are found in exhaled 
breath [67].  Alkanes are metabolised to alkyl alcohols by cytochrome P450 (CYP) – mixed function 
oxidase enzymes [75] and a number of studies have demonstrated that these enzymes are activated in 
lung cancer [76-79]. For example, poly-aromatic hydrocarbons in tobacco smoke induce CYP 1A1 and 
CYP 1A2 activity, resulting in the accelerated drug metabolism and activation of some procarcinogens 
[80]. Consequently, the biotransformation of volatile alkanes and mono methylated alkanes that are 
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produced by oxidative stress may be accelerated by CYP enzymes that have been activated in patients 
with lung cancer so producing aldehydes, alcohols and ketones in measurable quantities in breath [81].  
Acetaldehyde is related to ethanol metabolism [70].  Sources of endogenous acetone often are associated 
with oxidation of free fatty acids or ketosis as a result of starvation or untreated diabetes [82, 83], and 
isoprene, an unsaturated hydrocarbon, is endogenously produced as a by-product of cholesterol 
biosynthesis via the mevalonate pathway in mammals [84-86] and has been reported on breath using 
various analytical techniques [59, 71, 87, 88]. Methylamine is often linked with protein metabolism as 
mentioned in Table 1.2.   
VOCs Identified in Breath of Cancer Patients 
A number of studies have detected chemical compounds in breath samples from patients with and 
without lung cancer [19, 41, 79, 80, 89, 90]. Although the VOCs identified as markers of lung cancer 
differ between reports, the results have all shown significant variations between exhaled breath of lung 
cancer patients and healthy volunteers [89]. The source and physiological function of most lung cancer 
VOCs, however, are still unknown [90]. Some of them could be of exogenous origin and so be inhaled, 
absorbed from the lungs and metabolised in the body, and the metabolites excreted by expiration. Other 
VOCs that are of endogenous origin may be generated as products of internal metabolic processes [89].  
VOCs found in the breath of lung cancer patients include a wide range of aldehydes, alkanes and 
methylated alkanes containing C2-C11 carbons.   
A recent review by Saalberg (2016) summarises the compounds which have been identified as 
biomarkers of lung cancer in breath and in-vitro by various research groups, however some of the VOCs 
stated as biomarkers may be questioned as being of endogenous origin [91]. For example, benzene, 
ethyl benzene, toluene and xylene isomers which are known to originate exogenously (mainly 
petroleum and cigarette smoke by-products present in the environment) and styrene, which is also a 
petroleum product as well as a common GC column bleed product, have all been reported as biomarkers 
of cancer [20, 22, 23, 27, 66, 92, 93]. Also, some studies have reported other compounds related to 
cigarette smoking as markers of lung cancer, including alkenes and aromatic compounds such as 
acetonitrile, 2-methyl furan, 2,5-dimethyl furan, furan, 1,3-cyclohexadiene, 1,3-cyclopentadiene, 2-
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methyl-1-butene and 1,4-pentadiene, as well as N, N–Dimethyl acetamide, a known contaminant found 
originating from the Tedlar bags used for breath sampling [94, 95].  
As analytical technology rapidly advances, so has the detection of compounds in breath. Many 
compounds have been detected whose biochemical origin is unknown and many VOC metabolites 
reported as biomarkers have been found not to be disease specific. Hence, validation of the biomarkers 
is a necessary step in developing a specific and sensitive test for the early detection of lung cancer.  In-
vitro analysis of established cancer cell lines is an approach that should help identify endogenous VOCs 
and define the underlying mechanisms that lead to quantitative or qualitative changes in their 
concentrations in lung cancer breath.  
Cell Culture Metabolomics  
Validation of Biomarkers      
The integrated analysis of metabolomics and other ‘omics’ technologies may provide sensitive ways to 
detect changes related to disease and discover novel biomarkers [96]. Subtle changes in metabolism can 
be detected by analyses of the products of cellular processes which in turn can lead to development of 
prognostic models useful for early detection of cancer.   
The metabolome is downstream of the transcriptome and proteome, and is considered to be 
complementary to genomics, transcriptomics, and proteomics [97, 98].  Understanding the metabolome 
may also assist in identifying intermediate or provisional cancer biomarkers for establishing preventive 
or therapeutic approaches for health [96]. 
VOCs in breath can derive from cancer cells, healthy cells, immune cells and microbes [99]. Several 
studies have investigated the release of VOCs from human cancer cells in vitro [93, 99-102], for 
example headspace on-line measurements by selected ion flow tube mass spectrometry were able to 
detect acetaldehyde release from the lung cancer cell lines SK-MES and CALU-1 [102]. 
If some breath markers of lung cancer do derive from the cancer cells themselves, then there should be 
an overlap between the set of VOCs produced by cancer cells in culture and the VOCs detected in the 
breath of lung cancer patients. Comparison of the VOC profiles of breath analysis and cell cultures 
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(Table 1.3) reveals that, of the 68 VOCs detected in either breath or cell culture, 16 VOCs were detected 
in both. There were an additional 17 VOCs detected only in breath and 22 found only in lung cancer 
cell cultures and 13 VOCs found only in controls (non-transformed cell lines). This poor relationship 
indicates that in-vitro culture of lung cancer cells is not a good model for the production of VOCs in 
breath of lung cancer patients. A more detailed examination of the compounds identified shows that of 
the 16 compounds common to both cell culture headspace and lung cancer breath, five were straight 
chain alkanes and methylated alkanes, which is consistent with lipid breakdown associated with 
oxidative stress [37, 89]. Interaction of reactive oxygen species (ROS) with polyunsaturated fatty acids 
such as linoleic acid and palmitic acid in the cell membrane results in a series of reactions called lipid 
peroxidation. During the process of peroxidation of polyunsaturated fatty acids volatile alkanes are 
formed that can be excreted in breath unchanged or distributed throughout the body, partly metabolized, 
and then excreted in breath. 
  
Page | 10  
 
Table 1.3: Comparison of VOCs found in breath and in-vitro analysis of cells cultured under standard 
normoxic conditions. 
 
Class Compound Structure Breath In-vitro 
(Normal 
Cells) 
In-vitro 
(Cancer 
Cells) 
References 
Hydrocarbons       
Alkanes 
(Straight chain) 
  
    
 Pentane  
+a _ _ [5, 20, 
103]  
 Heptane  + 
_ _  [5, 20] 
 Octane  
+  b(hFB)  (A549) [20, 100] 
 Decane  
+ _  [19, 20, 
93, 104, 
105]   
 Undecane  
+ _  [19, 94, 
101] 
Alkanes 
(branched) 
2-methyl pentane 
 
+ _ _ [20, 99, 
103] 
 
2,3,3-
trimethylpentane 
   
_ (hFB&HBEp
C) 
(NCI-H2087) [100, 
101] 
 
2,3,4-trimethyl 
pentane 
 
_  _ [100]  
 
2,4-dimethyl 
hexane 
 
_  _ [100]  
 
2,3,5-trimethyl 
hexane 
 
_   (Calu-1) [100, 
101] 
 2-methyl heptane 
 
+ _ _ [19] 
 3-methyl heptane 
 
_  _ [100]  
 4-methyl heptane 
 
_  _ [100]  
 
2,4-dimethyl 
heptane 
 
+ _ (Calu-1) [7, 19, 
101]  
 
2,2,4,6,6-
pentamethyl 
heptane  
+ _ _ [20]  
 3-methyl octane 
 
+ _ _ [19] 
 4-methyl octane 
 
+ _ (Calu-1) [7, 101]  
 3-methyl nonane  
+ _ _ [19]  
Cycloalkanes 
1-methyl-2-pentyl 
cyclopropane  
+ 
 
_ _ [19] 
 
Methyl cyclo 
pentane  
+ _ + [19, 93] 
 Cyclo hexane 
 
+   [19]  
Alkenes 1-hexene  
+ _ + [19, 66, 
93] 
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Class Compound Structure Breath In-vitro 
(Normal 
Cells) 
In-vitro 
(Cancer 
Cells) 
References 
 1-heptene  + 
_ _ [19] 
 
2,4,dimethyl-1-
heptene  
_   (A549) [100]  
 
2-methyl -1,3-
butadiene 
(Isoprene)  
+ _ + [19, 20, 
93]   
Alcohols Ethanol  
+ _  (A549) [27, 100] 
 
2-methyl-1-
propanol 
 
_ (hFB) _ [100]  
 
2-methyl-2-
propanol 
 
_   (HBEpC) _ [100] 
 
3-methyl-1-
butanol 
 
+ (hFB) _ [92, 100] 
 2-ethyl-1-hexanol 
 
_ (hFB)  (NCI-H2087) [99]  
Aldehydes Formaldehyde 
 
+ _ _ [33] 
 Acetaldehyde 
 
+  (NCI-H2087, 
CALU-1) 
[99, 101, 
102]  
 2-methyl propanal 
 
_  (A549,NCI-
H2087, 
Calu-1) 
[99-101]  
 Butanal 
 
+ _ (A549) [21, 100] 
 Pentanal 
 
+ _ _ [17, 21, 
27]   
 Hexanal  
+  (NCI-H1666, 
Calu-1) 
[17, 19, 
21, 27, 
92, 93, 
106, 107] 
 Heptanal  
+ _ + [17, 19, 
21, 92, 
106, 107]  
 Octanal 
 
+  _ [17, 21]  
 Nonanal 
 
+ _ _ [17, 21]  
 prop-2-enal 
 
+ _     (Calu-1) [22, 101]  
 
2-methylprop-2-
enal 
 
_   (HBEpC)  (A549,NCI-
H1666,Calu-1) 
[100, 101, 
106]  
 
2-ethylprop-2-
enal 
 
_ _ (A549,Calu-1) [100, 101]  
 2-butenal 
 
_  _ [100]  
 
2-methyl-2-
butenal 
 
_ _ (A549,Calu-1) [100, 101] 
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Class Compound Structure Breath In-vitro 
(Normal 
Cells) 
In-vitro 
(Cancer 
Cells) 
References 
 2-methyl butenal 
 
_   (NCI-H2087) [99, 100] 
 3-methyl butenal 
 
_   [99-101, 
106]  
 Benzaldehyde 
 
_    (Calu-1) [100, 101]  
Ketones Acetone 
 
+    (A549)                [27, 100] 
 2-butanone 
 
+ _  (Calu-1) [101, 108] 
 2-pentanone 
 
+   [7, 15, 27, 
100]  
 2-hexanone 
 
_  _ [100] 
 3-pentene-2-one 
 
_  _ [100] 
 1-phenyl ethanone 
 
+ _ _ [19] 
Esters Methyl acetate 
 
_  _ [100]  
 n-propyl acetate 
 
_  _ [100] 
 n-butyl acetate 
 
_  _ [100] 
Ethers 
Methyl-tert-butyl 
ether  
_  (HBEpC)  (A549) 
 
(Calu-1) 
 
[98, 99] 
  
 
Ethyl-tert-butyl 
ether  
_  (hFB)  (A549) 
 
(Calu-1) 
 
 [100, 101] 
 
 
 
Aromatics 
Benzene 
 
+    (hFB) + [6, 19, 20, 
93, 100, 
104, 105] 
 Toluene 
 
+ _ _ [20]  
 Styrene  
+ _ + [6, 19, 20, 
93, 100, 
104, 105] 
 Ethyl benzene 
 
+ _ _ [92, 104, 
109] 
 Propyl benzene 
 
+ _ + [20, 93, 
105] 
 
Trimethyl 
benzene isomers  
+ _ + [19, 20, 
93] 
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Class Compound Structure Breath In-vitro 
(Normal 
Cells) 
In-vitro 
(Cancer 
Cells) 
References 
 Xylene isomers 
 
+ _ _ [19] 
Heterocyclics Tetrahydro Furan 
 
_ _   (Calu-1) [101] 
 Pyrrole 
 
_ _    (A549) [100] 
Nitriles Acetonitrile  
_ _  (Calu-1)  [101] 
 
All Compounds in breath are reported as present or not present in lung cancer patients breath. 
bCompounds in cell culture are either reported as increased or decreased arrows in quantity compared to medium controls or 
shown as “+” where reported without quantitation (cell lines indicated as hFB – Human fibroblasts, HBEpC – Human 
Bronchial Epithelial Cells) 
 
The remainder of the compounds common to breath and cell culture were alkenes, aldehydes and 
aromatic compounds, some of which are also associated with lipid peroxidation [34, 71]. Of the 22 
compounds found only in cell culture most were alcohols, ketones, esters and ethers (Table 1.3) 
suggesting that the VOCs produced by cancer cell culture are mostly oxidised breakdown products. 
Other analytical methods such as PTR-MS and SIFT-MS have also identified alcohols and aldehydes 
including isopropanol, formaldehyde and acetaldehyde in breath of lung cancer patients [8, 102]. 
The increased oxidation of alkanes to alcohols, esters and ketones in cell culture is perhaps, not 
unexpected when the environment in which cells are usually grown is considered. Most laboratories 
culture cells in air with 5% carbon dioxide, i.e. there is approximately 20% oxygen in the atmosphere 
surrounding the cells. This is in contrast to the in-vivo environment. 
Hypoxia  
Hypoxia in Cancer and Hypoxia-Inducible Factor 
Oxygen availability alters gene expression and metabolism in cells, hence raising the possibility that 
hypoxia will change the pattern of VOCs produced by the cancer cells. Tumours possess extensive 
regions of hypoxia relative to the corresponding normal tissue [110]. A number of adaptive responses 
are initiated during cellular hypoxic stress, including the activation of a group of transcription factors 
called Hypoxia Inducible Factors (HIFs). Hypoxia-Inducible Factor-1 (HIF-1) has been extensively 
studied as an endogenous hypoxia marker and its mechanism of accumulation under hypoxia is well 
understood [111, 112]. Another study emphasises the importance of hypoxia in tumours and in the 
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treatment of the disease [113]. HIF-1 regulates an increased production of VEGF [114]. VEGF induces 
neovascularisation but in tumours this happens in an irregular fashion and at a slower pace when 
compared to the proliferation rate of the tumour [115, 116]. This can result in poor blood supply and so 
further hypoxia.  
As described in Figure 1.1, in normoxia HIF-1 and HIF-1 subunits are constitutively expressed. 
While HIF-1 is rapidly degraded by the proteosomal system, the amount of HIF-1 remains constant. 
In hypoxia HIF-1 escapes degradation, binds with its partner HIF-1, and together they bind to a 
hypoxia-response element (HRE) in target genes in association with co-activators such as CBP/P300. 
This triggers the expression of multiple target genes that enable the tumour cells to adapt to and 
overcome the conditions of decreased oxygen by increasing oxygen transport, stimulating angiogenesis 
and regulating glucose uptake and metabolism [117]. 
 
Figure 1.1: Hif-1a in normoxia and hypoxia 
Activation of the hypoxia-inducible factor (HIF-1 transcription factor in normoxia and hypoxia. Figure 
adapted from Brahimi-Horn [118] 
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Tumour Energy Metabolism – Hypoxia  
Warburg Effect 
The induction of aerobic glycolysis is one of the strategic metabolic changes that meets the bio-energetic 
demands of the proliferating tumour [119]. Otto Warburg established that there is enhanced glycolysis 
in tumours despite the availability of oxygen, a phenomenon known as the “Warburg Effect” [120]. 
Also, he hypothesised that this phenomenon of “aerobic glycolysis” is due to dysfunctional 
mitochondria which may contribute to the malignant phenotype [121]. In recent years, it has been 
established that the activation of oncogenes or tumour suppressors may influence the switch from 
“cellular respiration” to “aerobic glycolysis” which in turn contributes to the Warburg effect [122-124].  
Non-transformed cells also convert glucose to pyruvate but then metabolise pyruvate through the 
tricarboxylic acid (TCA) cycle and mitochondrial oxidative phosphorylation (OXPHOS) as shown in 
Figure 1.2 [118]. The mitochondrial pathway requires oxygen and is much more efficient in ATP 
production than anaerobic metabolism; producing 38 versus 2 ATP molecules per molecule of glucose 
[118]. However, in an expanding tumour mass, characterised by low levels of oxygen and a high glucose 
consumption rate, anaerobic glycolysis can become the predominant pathway of ATP generation [125]. 
In addition to glycolysis, a recent study has shown that under hypoxia, autophagy is present and is also 
required to support ATP production [126]. 
Recent studies also show that increased mitochondrial reactive oxygen species (mROS) (explained in 
detail in section 4.2) may cause mutations in mitochondrial DNA (mtDNA) resulting in attenuation of 
mitochondrial function [124, 127]. 
A mechanistic link between apoptosis and metabolism has also been demonstrated by Iansante (2015) 
in human hepatocellular carcinoma (HCC). In their studies they show that PARP14 (poly (ADP-ribose) 
polymerase), an anti-apoptotic protein promotes aerobic glycolysis by regulating the activity of 
pyruvate kinase, a key regulator of the Warburg effect [128].  In summary, the activation of oncogenes 
or tumour suppressors along with the stabilisation of HIF can increase “aerobic glycolysis” through 
enhanced glycolytic flux and/or dysfunctional mitochondria. 
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Gene Expression – Hypoxia 
Under hypoxia, the metabolic switch from a respiratory phenotype to a glycolytic phenotype is achieved 
by HIF 1 induced up-regulation of glycolytic enzymes and down-regulation of mitochondrial oxidative 
metabolism [117, 129, 130]. Some of the genes which are activated under deprived oxygen conditions 
(HIF target genes) and involved in the process of enhanced glucose consumption are listed in Table 
1.4. When there is excess of glucose available, energy inefficient aerobic glycolysis is preferred over 
OXPHOS by the cells as glycolysis has the potential to produce ATP at a faster rate, providing the 
required energy to the rapidly growing tumour [131, 132]. Metabolic reprogramming thus serves two 
purposes, to rapidly provide ATP from glucose to supply energy to rapidly growing tumour cells, and 
to protect cells under low oxygen tension. 
Table 1.4: Target genes of HIF involved in glucose metabolism, cellular growth and proliferation under 
hypoxia. 
 
Glucose Transporter – GLUT1  
Glucose is an essential and critical carbon source for the biosynthesis of various macromolecules (lipids, 
proteins and nucleic acids) as well as providing an important substrate for ATP generation [141-143]. 
Gene Pathway involved Effect of Hypoxia 
GLUT1  
Glucose transporter 
Glucose metabolism 
Overexpressed in tumours 
[133] 
Pyruvate Kinase M2 (PKM2) 
Glycolytic enzyme 
Glucose metabolism and 
regulation of HIF1 
transcription 
Increased expression [134]  
Decreased expression [135, 
136] 
Lactate Dehydrogenase-A 
(LDHA)  
Glucose metabolism Increased expression [137] 
Pyruvate dehydrogenase 
kinase 1 (PDK1/PDHK1) 
Glucose metabolism 
(Switches metabolism of 
glucose from OXPHOS to 
aerobic glycolysis) 
Increased expression [138] 
Mammalian target of 
Rapamycin (mTOR) 
Cellular growth and 
proliferation 
Increased expression [139, 
140] 
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Glucose enters the cell through a family of membrane bound facilitated diffusion channels known as 
Glucose transporters or “GLUTs” [144]. Aberrant PI3K/AKT signalling induces the expression of high 
affinity glucose transporters GLUT1 and GLUT3 that are often found upregulated in tumours [133, 145-
148]. Transcriptional oncoproteins such as MYC along with HIF 1a induce and activate the expression 
of all the enzymes in the glycolytic pathway including glucose transporters [149-151].  
Pyruvate Kinase –M2 (PKM2) 
Pyruvate kinase M2, an isoform of the rate-limiting enzyme pyruvate kinase that catalyses the 
generation of pyruvate and ATP from phospho-enol pyruvate and ADP is involved in glycolytic energy 
production and plays a key role in metabolic adaptation under low oxygen tension [137, 152, 153]. 
PKM2 is also known to regulate the flux of carbons into both non-oxidative and oxidative branches of 
the pentose phosphate pathway, the former producing Rib-5-P which is a key intermediate in nucleotide 
biosynthesis [154, 155] and the latter producing NADPH for ROS detoxification [156-158]. Hence, 
PKM2 not only supports proliferation and tumour growth but also prepares the cancer cells to survive 
under oxidative stress. Furthermore, it has been established that PKM2 stimulates metabolic changes 
which favour proliferation, and is a key mediator and promoter of the Warburg effect [136, 159]. 
However, the biological impact of PKM2 in carcinogenesis and tumour growth is controversial [144].    
Pyruvate Dehydrogenase Kinase 1 (PDHK1/PDK1) 
Recent studies show that HIF1stabilization under hypoxia leads to the expression of Pyruvate 
Dehydrogenase Kinase 1(PDHK1) [138, 160], that phosphorylates and inhibits pyruvate 
dehydrogenase, limiting the conversion of pyruvate to acetyl - Co A and so shunting pyruvate away 
from entering Krebs cycle, resulting in a metabolic switch from OXPHOS to aerobic glycolysis [124] 
(see Figure 1.2). Consequently, PDHK1 induction decreases tricarboxylic acid (TCA) cycle activity so 
reducing oxygen consumption. 
Lactate Dehydrogenase A (LDHA) 
Lactate dehydrogenase A (LDHA) is an enzyme involved in conversion of pyruvate (generated from 
glucose) to lactate which is then secreted into the extracellular environment rather than oxidised to 
completion. By this conversion into Lactate, LDHA recovers the NAD+ required to maintain glycolysis 
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that is crucial to conserve tumour proliferation [161]. LDHA, in particular LDH5 tetramer is known to 
be overexpressed in lung cancer (NSCLC) under hypoxia [162].  
Mammalian Target of Rapamycin (mTOR) 
Mammalian target of Rapamycin (mTOR) is a kinase which is activated during cell stress conditions 
and integrates growth signals to enhance cell survival [144, 163, 164].  Protein translation, a vital 
process for tumour growth is enhanced through Akt-mediated mTOR activation [165-167]. It is 
constitutively expressed in advanced breast cancer [139, 140].  
 
Figure 1.2: Metabolic Reprogramming in Hypoxia 
Activation of HIF1-/ activates pyruvate dehydrogenase kinase 1(PDK1), an inhibitor of pyruvate 
dehydrogenase (PDH) which leads to the shunting of pyruvate away from the TCA cycle and instead it is 
converted to Lactate. Figure adapted from Semenza et al. [168]. Hexokinase 1 and 2 (HK1, HK2), Aldolase A 
(ALDOA), Enolase 1 (ENO1), Glyceraldehyde-3-phosphate (GAPDH), Phosphofructokinase L (PFKL), 
Phosphoglycerate kinase 1(PGK1), Pyruvate Kinase M2 (PKM2), Lactate dehydrogenase A (LDHA), Acetyl-
CoA (AcCoA), BCL2 family of mitochondrial proteins (BNIP3, BNIP3L).  
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Reactive Oxygen Species 
Reactive Oxygen Species such as superoxide anion, hydrogen peroxide, hydroxyl radicals, singlet 
oxygen, and lipid peroxyl radicals are ubiquitous molecules derived from oxygen that have accepted 
extra electrons and have the capacity to oxidize other molecules [169]. The formation of free radicals 
or oxidants is a well-established physiological event in aerobic cells [170]. Most of these chemically 
reactive molecules are short-lived and react with surrounding molecules while the antioxidants are 
generated to remove these oxidising agents. An imbalance between oxidant and antioxidant defences 
causes oxidative stress. This may in turn provoke oxidation of polyunsaturated fatty acids in cellular 
membranes. Increased ROS levels are associated with several pathophysiological states, such as 
neurodegeneration, cancer, mutagenesis, cardiovascular diseases and aging [171-173]  
Sources of ROS  
ROS production is an important component of pathogen killing in phagosomes [174] and peroxisomes 
[175, 176]. In addition, there are three other important sources of ROS – mitochondria, endoplasmic 
reticulum (ER) and cell membranes. 
The process of generation of ROS begins when molecular oxygen (O2) is reduced to form the superoxide 
anion (radical form) (Figure 1.3) which can cause potential damage if left unchecked. Superoxide 
dismutase (SOD1 – cytosolic, SOD2 – mitochondria and SOD3 – extracellular) are a class of metallo 
proteins that catalyse the conversion of the radical form (superoxide anion molecules) into much less 
damaging non-radical forms such as hydrogen peroxide (H2O2) and water. This hydrogen peroxide 
combined with superoxide anion are precursors of hydroxyl radicals generated via the Fenton Reaction.  
Hydrogen peroxide diffuses easily across the cell membranes and is relatively stable. Several studies 
identified that H2O2 acts as a crucial signalling molecule involved in controlling various processes 
including apoptosis and cell proliferation [177] by inactivating phosphatases. To maintain redox 
homeostasis, hydrogen peroxide is scavenged by anti-oxidant enzymes such as catalases and glutathione 
peroxidases (GTPX).  Clearly the mitochondria are the major cellular sources of Reactive Oxygen 
species (ROS) as by-products of mitochondrial respiratory chain [178]. Also, it has been established 
that mitochondria derived ROS (mROS) are involved in oxygen sensing [179]. Another source of ROS 
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results from oxidative protein folding in Endoplasmic reticulum (ER), along with an isoform of 
NAD(P)H oxidase – NOX4, present on the ER that produces hydrogen peroxide from molecular oxygen 
via a two electron reduction [176, 180]. Other NADPH oxidases (NOX1-5) and Dual oxidases 
(DUOX1-2) localised to various cellular membranes form the third functional source of ROS either in 
the form of superoxide anion or hydrogen peroxide [181-185].  NOX is also known to promote elevated 
glycolytic activity by providing additional NAD+, [186]. Various endogenous sources of ROS and the 
role of hypoxia in production of ROS are illustrated in Figure 1.3.  
 
Figure 1.3: Sources of ROS 
Intracellular sources of ROS under oxidative stress and hypoxia on ROS production. Increased hypoxia 
(indicated as ) leads to aerobic glycolysis and decreased mitochondrial activity and there is decreased 
antioxidant defences (indicated as ) during oxidative stress. Stabilisation of HIF1a by ROS from the 
mitochondrial complex III of electron transport chain which leads to the induction of a series of signalling 
cascades that aid tumour cells to survive and proliferate. This figure was produced using Servier Medical Art. 
www.servier.com.  
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ROS and Hypoxia 
ROS is known to inhibit prolyl hydroxylases (PHDs) which promotes the ubiquitination of HIF1a 
through hydroxylation. Seminal studies by Brunelle et al. demonstrated that not only H2O2 but also 
increased oxidative stress is required for stabilisation and accumulation of HIF1a which then initiates 
transcriptional targets of hypoxia-response genes that are involved in metabolic reprogramming to 
promote survival during hypoxia [187, 188]. Several studies have established that ROS derived from 
mitochondria complex III play a key role in tumorigenesis by inducing hypoxia-mediated transcription 
[179, 185, 189-193]. Recent studies demonstrated that mitochondrial generated ROS (mROS) play an 
essential role in stabilising HIF-1a subunit using  cells (cells lacking mitochondrial DNA) which were 
incapable of stabilising HIF-1a under hypoxia [189, 194]. As  cells lost important components of 
electron transport chain (ETC) they fail to exhibit mitochondrial respiration and hence do not produce 
mROS [127, 189]. In summary, oxidative stress leads to increased production of ROS which in turn 
activates transcription factors HIF and post-translational mechanisms which then produce metabolic 
changes leading to biochemical responses such as cell proliferation and survival.    
Lipid Peroxidation 
Lipids are a group of compounds with important biological functions in the human body. They make 
up between 30 and 80% of biological membranes by mass. Lipid peroxidation (LPO) is an oxidative 
degradation of polyunsaturated fatty acids. Biological cell membranes are made up of polyunsaturated 
fatty acids (PUFAs) which are known to be important in several physiological cell functions including 
cell homeostasis [195]. Polyunsaturated fatty acids are susceptible to oxidative degradation as they 
contain multiple double bonds. Also, various medical disorders such as obesity, atherosclerosis and 
cancer are characterised by altered levels of PUFAs or of their metabolites [196].  
Process of Lipid Peroxidation 
The general mechanism of lipid peroxidation consists of three steps: initiation, propagation and 
termination [197].   
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Initiation: Lipid peroxidation is a chain reaction – initiated by the interaction of reactive oxygen species 
(ROS) such as hydroxyl radical (OH*) with a fatty acid (RH) to generate a lipid (fatty alkyl) radical 
[198-200]. 
Propagation: The lipid free radical (R*) reacts rapidly with molecular oxygen to form a much more 
unstable fatty peroxyl radical (ROO*) which can easily extract a hydrogen from adjacent fatty acid to 
form hydro peroxides and a new lipid free radical. 
Termination: The above chain reaction is terminated by the interaction of two radical species to form 
non-radical products.  
Oxidative degradation of bio-membranes can initiate a complex cascade of events resulting in the 
formation of toxic end products as shown in Figure 1.4. There is abundant evidence that these end 
products (radicals, lipid hydro peroxides, and reactive aldehyde derivatives) modify proteins both in-
vivo and in-vitro [203-207]. Of many end products, malondialdehyde (MDA) and 4-hydroxynonenal 
(4-HNE) are categorised to have mutagenic and carcinogenic potential [208-218]  
 
Figure 1.4: The process of lipid peroxidation  
(figure adapted from Cadenas E) [219] 
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Historically, ethane (end product of oxidation of -3 fatty acid) and pentane (end product of oxidation 
of -6 fatty acid) are known to be the markers of oxidative stress and have been used to assess the 
extent of lipid peroxidation in subjects by breath test [62].   
Altered Cell Metabolism – Effect on VOC Output 
Metabolic Reprogramming – VOC profile changes 
Metabolic reprogramming of cancer cells is a complex interplay of transcription factors including 
HIF1a, oncogenes and growth factors. This altered metabolism not only delivers the required conditions 
for cell survival but may also influence the output of VOCs which can either be investigated in-vitro 
(cell culture metabolomics) or in-vivo by breath analysis.  
To summarise: oxidative stress causes overproduction of ROS initiating potential oxidative degradation 
of bio-membranes, DNA damage and proteins which then results in altered cell metabolism that has an 
effect on VOCs emanating from the cells as described in Figure 1.5: 
1. Lipid Peroxidation – relatively unstable ROS react with membrane lipids causing irreversible 
damage by initiating a chain reaction (Figure 1.4) which results in the formation of toxic by-
products which are capable of modifying proteins. 
2. Formation of DNA adducts – activates transcription factors and post-translational mechanisms 
which lead to altered gene expression. Discrete cohorts of genes can be either up or down-
regulated in response to hypoxia.  
3. Protein oxidation may also lead to altered cell metabolism.  
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Figure 1.5: Influence of ROS on cell metabolism 
Downstream effects of ROS lead to altered cell metabolism resulting in changes of VOC profile.  
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Conclusion 
 
Differences in the VOCs found in breath and in the headspace of cancer cell lines can be attributed to 
many causes such as different sampling methodology, mass spectral techniques and statistical 
approaches. Here we propose that cell culture conditions also play a role, as it is known that hypoxia 
induces autophagy and increased lipid peroxidation. This could explain the presence of alkanes and 
methylated alkanes found in breath of the lung cancer patients. Little attention has so far been paid to 
the in vitro culture conditions used to grow cancer cells. The routinely used normoxic culture conditions 
are likely to produce more alcohols and other oxidised products rather than the methylated alkanes that 
are more abundant in breath. Hence, oxygen controlled culture conditions should model more closely 
the in-vivo situation. This approach may help in validating breath VOC markers for diagnosis, clarify 
further how these compounds are produced and perhaps lead to the identification of novel VOC markers 
of cancer. 
This thesis will investigate the role of hypoxia to mimic the tumour microenvironment in metabolic 
reprogramming in lung cancer cells in culture, which may have implications for identifying useful 
markers for early diagnosis in lung cancer patients. This will be investigated based on the following 
objectives: 
1. Gene Expression Analysis of Hypoxia Target Genes.  
To elucidate the role of hypoxia on gene expression and ascertain the ideal culture conditions 
to better mimic in-vivo conditions. To achieve this, the total RNA extracted from the cells 
cultured under an oxygen gradient (5%, 2% or 1% O2 plus 5% CO2) was compared with total 
RNA from its normoxic (21% O2 plus 5% CO2) counterpart. [KPD1]This study will focus on 
genes and enzymes involved in the glycolytic pathway to determine the metabolic switch from 
a respiratory to a glycolytic phenotype. 
2. Measurement of Lipid Peroxidation (LPO) and Reactive Oxygen Species (ROS) between the 
two physiological culture conditions  
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To measure the free-radical mediated damage and to assess the extent of oxidative stress in the 
cells cultured under low oxygen conditions (2% O2) that might help to establish the possible 
biochemical origins of the VOCs. 
3. Analysis and comparison of VOCs from cultured cells in-vitro in two different physiological 
conditions – Normoxia (21% O2) and Hypoxia (2% O2) to obtain a VOC profile unique to 
Cancer Cells cultured in hypoxia. An anticipated outcome of the hypoxic environment would 
therefore be increased oxidative stress and a large proportion of metabolites being produced as 
a consequence of lipid metabolism leading to production of alkanes and methylated alkanes, 
and reduced oxidative degradation.   
Hypoxic culture conditions more closely mimic the conditions of cancer cell growth in vivo. Since 
hypoxia influences cell metabolism, subsequently it may influence the VOCs produced by the cancer 
cells.  
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Introduction 
This chapter describes general materials and methods used for the completion of this thesis. Methods 
specific to particular results chapters are included within the relevant chapter. 
Adenocarcinomic Human Alveolar Basal Epithelial cells - A549 Cells  
A549 cells were used in all the cell culture experiments and were obtained from the European Collection 
of Authenticated Cell Cultures through Sigma Aldrich, Australia. A549 cells were originally derived 
from a 58-year-old Caucasian male and are commonly used in cancer metabolomics studies [1-4]. 
Cells were grown in HEPES buffered DMEM supplemented with 10% heat inactivated FBS (Gibco 
ThermoFisher Scientific, Australia), 1% penicillin (Gibco) and 1% streptomycin (Gibco). Cells were 
grown either in a standard incubator (Brunswick Galaxy 170S) at 37˚C with 5% CO2 balanced against 
air (21% oxygen, 74% nitrogen), herein referred to as normoxia, or in a hypoxic chamber (Brunswick 
Galaxy 48R) at 5% O2, 2%O2 or 1% O2 plus 5% CO2 balanced against nitrogen at 370C, herein referred 
to as hypoxia. Cell viability was monitored using trypan blue dye exclusion and a Countess cell counter 
(ThermoFisher Scientific, Melbourne, Australia) after each sampling to determine the number of viable 
cells. The cell viability was greater than 98% for all the experiments. 
VOC Analysis 
Sample Preparation for GCMS Analysis 
After growing to sub confluence, A549 cells were seeded at 10 million cells per 50 ml media in a 250 
ml glass conical flask with stirring to maintain cells in suspension. The flask was sealed with a Teflon 
stopper and glass insert through which a coated fused silica fibre could be introduced for the sampling 
of volatile compounds in the headspace above the cell suspension. Flasks were placed on a magnetic 
stirrer (HD Scientific, Sydney, Australia) and were incubated in normoxia (21% O2) and hypoxia (2% 
O2) for 24hrs. The VOCs extracted from the headspace of culture were compared against the VOCs 
extracted from the headspace of media without cells. To eliminate the environmental VOCs, the air 
from both the incubators was sampled and analysed. 
Page | 54  
 
GCMS Analysis 
Volatile substances in the samples were collected by solid-phase micro extraction (SPME) using 
commercially available 75µm Carboxen-PolydimethylSiloxane (CAR/PDMS) fibres (Supelco, Sigma 
Aldrich, Australia).  The samples were loaded manually using a SPME holder (Supelco) and released 
by thermal desorption onto the injection port of the GCMS. The fibres were conditioned prior to use for 
all the GCMS analyses following the protocol listed by the manufacturer. Additionally, the SPME 
cleanliness was assessed by performing blank run with and without the fibres before each experiment. 
VOC analyses were performed using a Shimadzu QP2010 Ultra gas chromatography mass spectrometry 
(GCMS) equipped with mass selective detector (single quad mass spectrometer) (Shimadzu Scientific 
Instruments, Oceania Pty Ltd.).  
A 25m x 0.32mm x 5µm PoraBond Q PLOT column was used (Pacific Laboratory Products, Blackburn, 
Australia) with an initial temperature of 90oC for 5 min followed by a temperature ramp of 5oC/min up 
to 250oC which was held for 4 min. The temperature was then increased at a rate of 5oC/min to 280oC 
and held for 3 min. The helium flow rate was 1.48 ml/min. Ionisation of separated compounds was 
performed by Electron Impact ionisation at 70 e.V. Total ion current (TIC) mode with full scan range 
of m/z=30 to m/z=600 was employed. The detected substances were identified by spectral match with 
NIST 2011 Spectral library (Stanton Scientific, Australia) and retention times obtained from the 
standards where these were available. 
Calibration Curve 
Preliminary calibration was performed using a specialty mix of alkanes with C2-C6 carbon skeleton at 
a concentration of 100 and 1000 PPM (Scotty Analysed Gases, Supelco Analytical, USA). After the 
qualitative analysis was performed to determine the VOCs unique to hypoxic conditions, a five-point 
linear calibration curve was obtained for compounds of interest using a custom mixture of standard 
compounds (AccuStandard Inc., Connecticut, USA), where available (n-pentane, 3-methyl hexane and 
2-nonanone) at concentrations of 10, 30, 100, 300 and 1000 ppm. The standard mixtures were collected 
using 75m CAR/PDMS by solid-phase micro extraction and were loaded using the auto sampler (AOC 
5000, Shimadzu Scientific Instruments) and released by thermal desorption onto the injection port of 
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the GCMS. For each compound the regression was linear from 10 to 300 ppm. LOD and LOQ were 
calculated from the linear regression using the formula LOD = 3 x SD/slope and LOQ = 10 x SD/slope 
where SD is the standard deviation of the Y-residuals. 
Gene Expression 
RNA Extraction 
Total RNA was extracted from stationary cultures of A549 cells using TRI-Reagent (Sigma Aldrich, 
Castle Hill, Australia) according to the manufacturer’s protocol. Cells were collected in TRI-Reagent 
and RNA was separated in chloroform by centrifugation at 12,000 RPM for 15-minutes at 40C. RNA 
was precipitated with isopropanol and incubation on ice for 10 minutes. Samples were then centrifuged 
at 10,000 RPM at 40C for 10 minutes. The resulting RNA pellet was washed twice in 75% ethanol 
before final resuspension in 25 l of RNAase free water. The quality and quantity of RNA was measured 
using a Nanodrop spectrophotometer (Thermo Scientific). All RNA samples used had a 260/280 quality 
ratio of 1.95-2.00. 
cDNA Synthesis 
cDNA was synthesised following the manufacturer’s instructions using a High Capacity cDNA 
synthesis kit (ThermoFisher Scientific, Australia). A 20 l reaction was prepared by adding a solution 
containing reaction buffer, random primers, free nucleotides and reverse transcriptase to a 2 g of total 
RNA and incubated according to the protocol in Table 2.1: cDNA synthesis temperature conditions. A 
final working concentration of 5 ng/l was obtained by diluting the completed reaction to 400 l in 
nuclease free water. The resulting cDNA obtained was stored at -20°C.  
Table 2.1: cDNA synthesis temperature conditions  
 Annealing Extension Inactivation Hold 
Temperature 25°C 37°C 85°C 4°C 
Time 10 minutes 120 minutes 5 minutes ∞ 
́ 
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Primer Design 
Primers were designed using the NCBI Primer Blast Tool and purchased from Bioneer Pacific (Kew 
Australia). All primers were analysed using BLAST to attain target gene specificity and avoid 
amplification of genomic DNA, with at least one primer in the set spanning an exon-exon junction. To 
ensure that all the PCR reactions could be run with the same annealing temperature, all the primers were 
designed to have a melting temperature close to 60°C.  
PCR Primer sequences: 
ACTB 5 ́ -CGCGAGAAGATGACCCAGAT-3 ́ 5 ́-GAGTCCATCACGATGCCAGT- 3 ́ 
EEF2 5́ -AGGCTGCCATGGGCATTAAA- 3́ 5́ -AGGCGTAGAACCGACCTTTG-3́ 
GLUT1 5 ́ -TGGCATCAACGCTGTCTTCT- 3 ́ 5 ́ -AGCCAATGGTGGCATACACA- 3 ́ 
LDHA 5 ́ -GGAACTGGATCGGTTGGTGT -3 ́ 5 ́ -AAGGGCTGCCATGTTGAAGA- 3 ́ 
mTOR 5 ́-AAGCCGCGCGAACCTC- 3 ́ 5 ́ -CTGGTTTCCTCATTCCGGCT – 3  ́
PDHK1 5 ́-CTCAGGACACCATCCGTTCA- 3 ́ 5 ́-
ACCATGTTCTTCTAGGCCTTTCAT-
3 ́ 
PKM2 5 ́ -ATGCAGCACCTGATAGCTCG- 3 ́ 5 ́ -AGGCTCGCACAAGTTCTTCA – 3  ́
 
Real-time PCR 
A RealPlex PCR detection system (Eppendorf, North Ryde, Australia) was used to perform quantitative 
PCR (qPCR) in triplicate on at least three independent RNA preparations.  Target cDNA levels were 
analysed in 10 µl reactions with SensiMix SYBR No-ROX (Bioline, Alexandria, Australia). qPCR was 
performed using 4 µl of cDNA template (20 ng) and primers at a concentration of 1 µM following the 
parameters as described below. 
PCR Cycle Parameters 
The thermal cycling conditions for activation were 2 minutes at 950C followed by 40 cycles of 15 
seconds at 950C for denaturation, 15 seconds at 590C for annealing and 10 seconds at 720C for extension.  
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Gene Expression Analysis 
The relative expression formula was used to analyse the real-time qPCR data. Eukaryotic elongation 
factor 2 (Eef2) or β-Actin (ACTB) were used as reference gene (REF) and the gene of interest (GOI) 
cycle threshold (Ct) was made relative to the REF gene using the following equation: 
CtGOI – CtREF = ΔCt 
Where CtGOI is the cycle threshold for the gene of interest, CtREF is the cycle threshold for the gene of 
reference. The ΔCt values were transformed to fold changes in expression using the relative 
expression equation:  
Relative Expression = 2-ΔCt 
To test for statistical significance, two-way ANOVA analysis with post-hoc Bon Ferroni test was 
performed on ΔCt values in the normoxic versus the hypoxic group as the least transformed relative 
data ΔCt, is the most appropriate value to analyse [5]. The threshold of statistical significance was set 
to < 0.05. The standard deviation of the relative expression of at least three independent replicates are 
shown as the error bars on gene expression graphs.  
Confocal Microscopy 
A Nikon Eclipse Ti-E confocal microscope with an attached 37°C chamber was used to perform live 
cell imaging. Cells were washed twice with PBS buffer and 1 ml of fresh warm media (without phenol 
red indicator) and then imaged.  25 mM HEPES buffer was included in the imaging media to buffer pH 
fluctuations brought on, by the change from 5% CO2 in the cell culture incubator to the conditions of 
microscope incubation chamber. To capture total cell fluorescence, cells were imaged using a 60X oil 
immersion objective over a 15 µm z-range with an image captured every 1 µm.  
Lipid Peroxidation Imaging 
A ratiometric fluorescent reporter for lipid peroxidation, Image-iT Lipid peroxidation kit 
(ThermoFisher Scientific, Australia), was used to measure free-radical damage in cells. Upon oxidation, 
the fluorescence emission peak shifts from ~590 nm (red) to ~510 nm (green).  A549 cells grown to 
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60% confluence were washed twice in PBS and loaded with 1µl of Lipid peroxidation sensor 
(ThermoFisher Scientific) in 1 ml DMEM medium with 10% FBS and without phenol red and incubated 
at 37°C for a total of 30 minutes. For a positive control, cells were incubated for 20 minutes with 100 
µM of cumene hydroperoxide to induce lipid peroxidation. Imaging of the treated cells was performed 
as described above. All experiments were performed on at least three independent samples. 
Fluorescent ROS Imaging 
Increased oxidative stress in live cells can be assessed by the measurement of ROS production using an 
Image-iT LIVE Green Reactive Oxygen Species Detection kit (Life Technologies) according to the 
manufacturer’s protocol. Cellular ROS was labelled with a final concentration of 25 µM carboxy-
H2DCFDA (5-(and-6)-carboxy-2 ́,7 ́- difluorodihydrofluorescein diacetate), a compound that fluoresces 
when oxidised (Excitation/ Emission: 492-495 nm/517-527 nm) along with 1 µM of Hoechst 33342 
was added in the final 5 minutes of incubation. Cells were washed twice with PBS before adding 1 ml 
of fresh warm media prior to imaging. A known inducer of ROS production, tert-butyl hydrogen 
peroxide (TBHP) was used for a positive control with a final working concentration of 100 µM and the 
cells were incubated for 60 minutes and imaged as described above. Cells were imaged using 60X 
objective with oil immersion and the experiment was repeated on at least three individual samples. 
Fluorescence Intensity Analysis 
1) Quantification of Lipid Peroxidation in A549 Cells.  
The extent of lipid peroxidation was measured using a ratiometric sensor where the fluorescence 
emission peak shifts from red (590nm) to green (510nm) when oxidised. The pixel density analysis 
was done on each individual cell using ND2 software, where the minimum ratio was kept at zero 
and maximum at two. Also, the background was removed by selecting a region without any visible 
fluorescence for all the groups. Bright spots on the acquired image, where pixel saturation was 
detected (using ND2 software) have been excluded by drawing regions of interest (ROIs).  
 
2) Quantification of ROS in A549 Cells. 
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Pixel density analysis of ROS production obtained from the confocal experiments was performed 
using ImageJ software (http://imagej.nih.gov/ij/index.html) on each individual cell for all the 
groups after background subtraction. 
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Abstract 
Metabolic reprogramming is a hallmark of cancer. Hypoxia is known to induce similar adaptive changes 
in cell metabolism that include a switch from oxidative to glycolytic metabolism, which is mediated at 
the transcriptional level by HIF1. Metabolic adaptation to hypoxia is facilitated by the activation of 
genes involved in the glycolytic pathway by the HIF1 subunit HIF1a. Furthermore, mitochondrial 
function is reduced by HIF1 through upregulation of pyruvate dehydrogenase kinase 1 (PDHK1), which 
inactivates the key TCA cycle enzyme pyruvate dehydrogenase (PDH). This shunts pyruvate away from 
the TCA cycle and towards conversion to lactate by the hypoxia-inducible enzyme LDHA.  In this study, 
we reveal the effects of oxygen concentration on gene expression in A549 lung cancer cells. A 
quantitative RT-PCR analysis demonstrated a significant upregulation of the glucose transporter 
(GLUT1) and the key TCA regulatory gene PDHK1 in cells cultured under 2% and 1% O2. This study 
demonstrates that oxygen concentration in-vitro plays a fundamental role in regulating metabolic 
reprogramming in A549 cells through altering the expression of HIF1 target genes.  
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Introduction 
The biosynthetic pathways in cells are known to be altered to promote adaptation and improve survival 
under environmental stress. A good example is the adaptive response of cancer cells to hypoxia where 
the metabolic switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis is an important 
step in cell proliferation and survival.  In 1920, Otto Warburg discovered that tumours show increased 
glucose consumption and altered glucose metabolism despite the availability of oxygen, a phenomenon 
known as the “Warburg Effect” [1]. This principle is utilized in clinical settings, through uptake of 
isotope labelled deoxyglucose using PET (positron emission tomography) imaging, also known as 
FDG-PET, to image increased glucose uptake by tumours. 
Previous studies have established that HIF 1 is stabilised in hypoxia and is a “master regulator of oxygen 
homeostasis” [2, 3]. It also plays a crucial role in the pleiotropic response observed under hypoxia [4-
11]. HIF 1 not only activates the transcription of genes encoding proteins that mediate glycolysis, 
glucose entry etc., but in cancer it also promotes invasion and metastasis [11-15] (see Figure 1.2) 
In A549 cells, despite the low yields of ATP (only 2ATP), aerobic glycolysis is preferred over the TCA 
cycle (30 or more ATP), and is achieved by increasing both glucose up-take and its conversion to 
pyruvate. This is attained by increasing HIF-mediated expression of genes and enzymes involved in the 
glycolytic pathway including the glucose transporter, GLUT1 [16, 17]. The pyruvate is redirected away 
from OXPHOS and converted to lactate by increased HIF-mediated expression of two key enzymes – 
lactate dehydrogenase A (LDH-A) [18] and Pyruvate dehydrogenase kinase 1 (PDHK1) [2, 3, 19]. 
Another pathway which is modified by HIF is the mammalian target of rapamycin (mTOR). Hypoxia 
suppresses expression of mTOR to save on energy-consuming protein synthesis so enhancing cellular 
adaptation [7, 20-22]. The glucose metabolism is also controlled by the oncoprotein, MYC which 
stimulates the transcription of LDH-A, PDHK1 and Pyruvate kinase M2 (PKM2) [23-25] and increased 
expression of PKM2 is observed in many cancers including lung cancer [26, 27]. Hence, the Warburg 
effect is the result of activation of several pathways largely mediated by HIF1 and MYC.                                                                                                                                                                                                                                                                                                                                                                      
In the present study, we investigate the effect of low oxygen concentrations on gene expression of HIF 
1 target genes (PDHK1, mTOR, PKM2 and LDH-A) including the glucose transporter GLUT1 in A549 
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lung cancer cells. This was achieved by qPCR on A549 cells exposed to 1% O2, 2% O2 and 5% O2 
compared to standard cell culture conditions (21% O2). The results showed that significant gene 
expression changes were detected at 2% O2 and 1% O2 compared to controls. 
Methods and Materials 
Cell Culture  
The lung carcinoma cell line A549 was grown in DMEM with HEPES buffer media supplemented with 
10% heat inactivated FBS (Gibco), 1% penicillin (Gibco) and 1% streptomycin (Gibco) at 37˚C with 
5% CO2. The cells were exposed to Nitrogen balanced against air to give Oxygen concentrations of 1% 
O2, 2%O2 or 5% O2 plus 5% CO2 at 370C in a hypoxic chamber. Normoxia was air (approximately 21% 
O2, 74% Nitrogen) and 5% CO2 at 370C in a conventional incubator. Each experiment was performed 
with a Normoxic control. Cell viability was monitored after each sampling to ensure the presence of 
viable cells using a Countess cell counter (Life Technologies Pvt. Ltd, Australia.) which was measured 
to be greater than 98% for all the experiments.  
RNA Extraction and cDNA Synthesis 
Gene expression analysis was performed as described in Chapter 2: Methods and Materials (Section 
2.4) in this thesis. Briefly, total RNA was extracted from A549 cells using TRI-Reagent and the 
phenol/chloroform method. After cDNA synthesis gene expression was measured using specific 
primers and quantitative real-time PCR. Expression was compared to -Actin (ACTB) and Eukaryotic 
Elongation Factor (EEF2) as controls. 
Statistics 
Data from three independent biological replicates of the qPCR experiments were analysed for statistical 
significance by two-way ANOVA with Bon Ferroni post-hoc tests. Changes were considered 
statistically significant when the P value was ≤ 0.05.  All statistical analysis was performed on Ct 
values as the least transformed data. The standard deviation of the relative expression of at least three 
independent replicates are shown as the error bars on gene expression graphs.  
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Results 
Cellular exposure to hypoxia results in altered gene expression  
 
To elucidate the role of hypoxia on gene expression in A549 cells, expression levels of hypoxia-
associated genes in cells cultured under different oxygen conditions were investigated. The HIF 1 target 
genes analysed included the GLUT1 glucose transporter and genes involved in the glycolytic pathway 
(GLUT1, PDHK1, PKM2, mTOR and LDHA, see Chapter 1; Section 3.2, Table 1.4).  Data analysis 
using either control gene, ACTB or EEF2, gave similar results. The data shown in this results section 
were derived using the ACTB gene as the control (see Appendix I for EEF2 data).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
The glucose transporter GLUT1 was increased in expression level in A549 cells cultured under 1% and 
2% O2 compared to cells cultured under normoxic conditions (  
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Figure 3.1A, 1% O2 p = 0.04, 2% O2 p = 0.001). Cells cultured under 1% and 2% O2 showed between 
3 and 5 fold increased expression compared to normoxic controls. There was no statistically significant 
increase in GLUT1 expression in 5% O2. 
PDHK1 expression was also increased in A549 cells cultured under 1% O2 and 2% O2 (3-fold and 5-
fold increase compared to controls, P = 0.02 and 0.001 respectively,   
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Figure 3.1B). Expression levels of PDHK1 in cells cultured in 5% O2 were similar to normoxic cultures.  
There were no statistically significant changes observed in the levels of expression of Pyruvate Kinase 
M2 (PKM2), mammalian Target of Rapamycin (mTOR) or Lactate Dehydrogenase A (LDH-A) (  
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Figure 3.1C, D and E). Each of these genes had Ct values of 22.1, 23.8, 28.0 suggesting low expression 
in controls, which did not alter with changes in O2. 
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Figure 3.1: Relative mRNA expression of HIF1 target genes. 
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Figure Legend 
 
Figure 3.1: Relative mRNA expression of the 
hypoxia associated genes relative to the 
housekeeping gene, ACTB in A549 cells 
cultured under various oxygen concentrations 
compared to their controls. Relative 
expression of A. GLUT1, B. PDHK1, C. 
LDH-A, D. mTOR and E. PKM2 mRNA to 
ACTB. For each graph, the normoxic control 
for each low oxygen condition is shown 
(Norm-1, Norm-2 and Norm-5). Error bars 
indicate the SD from three independent 
biological samples. 
*P < 0.05, **P < 0.005. 
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Discussion  
Hypoxia results in metabolic reprogramming through HIF mediated changes in a substantial number of 
genes involved in metabolism [2, 19, 28-30]. Aerobic glycolysis in cancer cells is of particular interest 
as it plays a crucial role in cellular adaptation and cancer invasion and metastasis [11-15]. HIF 1 plays 
pivotal roles in the metabolic transformation from respiratory to glycolytic phenotype in three ways; 
first by increasing glycolytic flux from glucose to pyruvate through activation of upstream glucose 
transporters and glycolytic enzymes, second by inducing the expression of PDHK1 that inhibits the 
pyruvate from entering the TCA cycle and third by inducing the expression of LDHA which converts 
pyruvate to lactate [2, 31]. Cancer cells usually show the Warburg effect where glycolysis is the 
preferred pathway for glucose metabolism despite the availability of oxygen [32, 33]. 
Increased glucose uptake is facilitated by high levels of expression of the glucose transporter, GLUT1. 
In the cells cultured under hypoxia a significantly higher level of expression of GLUT1 was observed, 
which is consistent with increased uptake of glucose identified in other studies of A549 cells [34]. 
Furthermore, there was a difference in GLUT1 expression in cells cultured under differing levels of 
hypoxia with a 3-fold change in the cells under 1% O2 compared to a 5-fold change under 2% O2. 
Pyruvate dehydrogenase kinase 1 (PDHK1) regulates glucose metabolism through phosphorylation of 
the pyruvate dehydrogenase (PDH) complex leading to its inactivation. Several studies have reported 
an increased expression of PDHK1 in cancer cells including gastric and acute myeloid leukaemia [35, 
36]. The suppression of PDH by PDHK1 results in the reduction of mitochondrial respiration, thereby 
supporting the cellular adaptation to hypoxia. The activation of PDHK1 may be a strategic regulatory 
switch leading to the Warburg effect. The results of this study show overexpression of PDHK1 in cancer 
cells cultured under hypoxic conditions (1% O2 and 2% O2 only) compared to their normoxic controls. 
A significant 3-fold increase in the expression of PDHK1 was detected in cells exposed to 1% O2 and 
a significant 5-fold increase in cells exposed to 2% O2 compared to normoxic controls. This 
upregulation in hypoxia is consistent with other studies [2, 3].  
One interpretation of increased GLUT1 and PDHK1 in A549 cells grown in hypoxia is that A549 cells 
still utilise OXPHOS when cultured in normoxic (environmental air) conditions. Liu et al., using 
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NSCLC tissues and A549 cell lines, demonstrated a significant upregulation of PDHK1 and a pivotal 
role in metabolic reprogramming under hypoxia leading to what they referred to as “enhanced” Warburg 
effect [37]. Similarly, several studies have established that cancer cells in hypoxia show increased 
glycolysis or increased GLUT1 and PDHK1 expression, [2, 3, 38]. Furthermore, recent studies have 
established that the overexpression of PDHK1 attenuates mROS generation and protects cells from 
hypoxia-mediated apoptosis [2, 39-41]. These results suggest a continued role for mitochondrial 
OXPHOS in cancer cells alongside the increased preference for glycolysis as an energy source. In this 
context the increased GLUT1 and PDHK1 mRNA expression in hypoxia demonstrated here indicates a 
further shift towards glycolysis and away from OXPHOS in A549 cells.  
Although, an upregulated expression of PKM2, mTOR and LDHA has been indicated in the previous 
studies on various tumours (Chapter 1, Table 1.4), in A549 cells only PKM2 has been reported to be 
overexpressed. Interestingly, there were no statistically significant changes observed in the expression 
of the above stated genes in this study on A549 cells.  It is noteworthy that a recent study found that 
mTOR responds to reduced pH rather than hypoxia per se as previously believed [42]. The cells in this 
study were grown in HEPES buffered media to prevent acidification so this may explain no change in 
mTOR expression.  
There were no significant gene expression changes observed in the cells exposed to 5% O2 in-vitro 
possibly due to the fact that 5% of oxygen is close to physiological normoxic conditions.  The pO2 in 
the muscle cells in vivo is close to 5% O2 [43], whereas in cancer cells the diffusion of oxygen is far 
less than in healthy tissues due to the high rate of cell proliferation in cancer which results in chaotic 
vasculature giving rise to hypoxic regions (Section 3.1, Chapter 1 of this thesis). The diffusion limit of 
oxygen within tissues has been measured to be 150m [44-47]. This means that once a tumour grows 
to greater than 300 m diameter or approximately 15-20 cells across, the cells in the centre experience 
hypoxic conditions. The findings reported here are consistent with previous studies, where synchronised 
activation of glucose absorption and metabolic reprogramming occurs in cancer cells and has been 
identified as a potential therapeutic target [48].  
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Conclusion 
The understanding of how hypoxia effects gene expression and hence tumour progression and survival 
has attracted substantial interest. There are many in-vitro studies analysing gene expression in cancer 
cells. To ensure such studies are physiologically relevant, there is a need to identify the ideal culture 
conditions that best mimic in-vivo conditions.  From the above findings, cells cultured under 2% O2 
have increased GLUT1 and PDHK1 expression and possible reprogramming of glucose metabolism. 
Hence in order to mimic the in-vivo conditions found in tumours in cell culture models, it is preferable 
that the percentage of oxygen should be maintained at less than 5%. 
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Abstract 
The activity of reactive oxygen species (ROS) in cancer cells under low oxygen conditions is well 
established but the damage it causes still remains unclear. Lipid peroxidation (LPO) is a complicated 
process that involves the formation and propagation of lipid radicals that cause structural damage and 
produce a variety of cytotoxic metabolites. These metabolites modify proteins both in-vivo and in-vitro, 
and can influence cell metabolism. This led to our hypothesis that hypoxic cultures have altered lipid 
peroxidation and ROS production. Here we investigated whether hypoxia stimulates free-radical 
mediated damage to lipids. To achieve this, LPO and ROS were measured in A549 cells using 
fluorescent reporter dyes and confocal microscopy. Importantly, the peroxidation-sensitive change in 
fluorescence of BODIPY® 581/591 C11 at red (590 nm) relative to that at green (510 nm) facilitated 
ratio-metric assessment of LPO in cells.  An increase in LPO was observed in the cells cultured under 
low oxygen conditions. However, there was a slight decrease in the production of ROS in hypoxic 
cultures. In conclusion, hypoxia stimulates LPO free-radicals and attenuates ROS radicals in A549 cells, 
the combined effect of which may serve to equip the cells to adapt to and proliferate under low oxygen 
conditions. 
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Introduction 
Lipid peroxidation is the oxidative degradation of cellular lipids that are rich in polyunsaturated fatty 
acids (PUFAs) by reactive oxygen species. Oxidative modification of PUFAs affects cell membrane 
properties and signal transduction pathways [1, 2] and is implicated in various pathological processes 
such as atherosclerosis, cancer, diabetes, acute lung injury [3-7] as well as the neurodegenerative 
disorders including Alzheimer’s and Parkinson’s disease [8-10]. 
Hypoxia is associated with increased lipid peroxidation products in animal tissues (for review see [11]) 
and several other studies have reported increased levels of MDA (malondialdehyde), a known 
biomarker of lipid peroxidation, in human breast cancer and lung cancer [12-15]. 
Free radicals are generated as a by-product of cellular respiration (mitochondrial respiratory chain) [16] 
and other endogenous sources (see Section 4.1, Chapter 1 of this thesis). Due to their instability and 
chemical reactivity, they readily react with the cellular membranes which are rich in lipids producing 
alkyl radical. Once the alkyl radical is generated the cascade of lipid peroxidation follows (see Section 
5.1, Chapter 1) causing oxidative damage to the cells under oxidative stress. Anti-oxidant enzymes such 
as catalases and glutathione peroxidases scavenge ROS to protect cells from cytotoxic effects.  
Additionally, the pentose phosphate pathway, generates ribose 5-phosphate and nicotinamide adenine 
dinucleotide phosphate (NADPH) which are vital to defend the cells from ROS [17-19].  
It has been established that in many cancer cells, hypoxia induces the expression of an isoform of 
glycogen phosphorylase (PYGL) that alters glycogen metabolism leading to the generation of glycolytic 
intermediates and NADPH, a key ROS scavenger [17, 20-22]. Furthermore, other studies have 
demonstrated that over-expression of uncoupling protein 2 (UCP2) (protein that is expressed in the 
inner membrane of the mitochondria) inhibits ROS-mediated apoptosis under hypoxia in cancer cells 
[23-27]. 
The aim of this study was to determine whether hypoxia alters ROS and lipid peroxidation in A549 
lung cancer cells. Changes in free-radical mediated oxidative damage in cancer cells under low oxygen 
conditions could aid in establishing a biochemical origin of VOCs produced in lung cancer. 
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Methods 
Cell culture 
 
A549 cells were cultured in DMEM supplemented with 10% foetal bovine serum, 1% 
penicillin/streptomycin and HEPES buffer (Life Technologies) with 5% carbon dioxide in both 
normoxic (atmospheric oxygen) and hypoxic (2% O2) conditions. Cells were seeded into imaging 
dishes (Mattek Corporation, Ashland, MA) for confocal microscopy. Imaging was performed as 
described in Section 2.5, Chapter 2 –Materials and Methods. 
Detection and Analysis of Lipid Peroxidation in A549 cells  
 
The cells were stained with BODIPY® 581/591 C11 at a final concentration of 10 M and fluorescence 
imaging was performed using 590 nm and 510 nm emission filters using a Nikon Eclipse Ti-E confocal 
microscope as described in Section 2.5.1 (Chapter 2 –Materials and Methods of this thesis). In order to 
minimise pixel saturation, initial calibration on cells with the indicator and an inducer of lipid 
peroxidation was performed and excitation emission intensities adjusted accordingly. The lipid 
peroxidation was determined by quantitating the pixel density at 510 and 590 nm emission on each cell 
and calculating the ratio of the emission fluorescence intensities (510nm/590 nm). This was achieved 
by setting up an automatic calculation of ratios using ND2 software for all the groups. All experiments 
were repeated at least three times and the results shown are from one typical experiment.  
To determine co-localisation of Lipid Peroxidation and detect any Structural Changes of 
Mitochondria in A549 cells under hypoxia. 
A549 cells cultured under hypoxia (2% O2) and Normoxia (21% O2) were incubated for 30 minutes 
with 200nM MitoTracker (mitochondria probe) to label the mitochondria and 10M Lipid Peroxidation 
Sensor. To see if the LPO was co-localised to mitochondria data for both the channels was extracted as 
red (Far Red) and green (FITC) and the images overlayed using ImageJ software.  
Detection and Analysis of ROS in A549 cells 
Cellular ROS was detected and measured by staining the A549 cells with H2DCFDA at a final 
concentration of 25 M for 30 minutes. Hoechst 33342 was added five minutes prior to analysis to 
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identify nuclei (blue) as described in detail in Section 2.5.2 (Chapter 2: Materials and Methods). In 
order to correct for auto fluorescence, initial calibration on cells without the ROS indicator dye was 
performed. After confocal imaging, pixel density was calculated on individual cells from both channels 
(blue and green) for all groups. The integrated optical density (IOD) for all the cells per field of view 
was quantified using ImageJ software and averaged for each image. Three biological replicates were 
performed and the data expressed as the mean and standard deviation of the biological replicates. 
Statistical significance was by Students t-test.  
Results 
A549 cells cultured under hypoxic conditions show increased Lipid Peroxidation 
The effect of hypoxia on peroxidation of unsaturated lipids in A549 cells was assessed. Cells cultured 
under low oxygen conditions had a visible increase in green fluorescence (510 nm) and decrease in red 
fluorescence (590 nm), indicative of lipid peroxidation compared to the cells cultured under normoxic 
conditions. Accordingly, the ratiometric analysis demonstrated a high ratio confirming a higher level of 
constitutive lipid peroxidation in hypoxic cultures compared to normoxic cultures of A549 cells ( 
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Hypoxic cultures show an increase in lipid peroxidation compared to normoxic cultures. Lipid 
peroxidation in live cells was assessed by confocal fluorescence microscopy and the pixel density of 
each cell was measured. A549 cells were incubated for 30 minutes with 10M Lipid Peroxidation 
Sensor (a ratio metric dye). Scale bar, 50m. A high ratio (dark blue/green) indicates high levels of 
lipid peroxidation and a low ratio (light blue/magenta) indicates no lipid peroxidation (colour legend 
on the far right in the pictures). (A) Positive Control where lipid peroxidation was induced by treating 
the cells with Cumene Hydroperoxide. (B) Under basal conditions, normoxic cultures show no 
peroxidation whereas hypoxic cultures show constitutive lipid peroxidation (C). (D) Scatter plot of 
normalised pixel frequency against the ratio of fluorescence at 510 nm/590 nm (green/red) indicates 
a higher pixel density at the low ratio (peak at 0.1) in normoxic cultures compared to hypoxic cultures 
(peak at 0.5) and the positive control (peak at 1.0). 
 
 
 B-C). This was confirmed by plotting the frequency of pixels at each 510/590 ratio for normoxic and 
hypoxic cultured cells and positive control cells with induced lipid peroxidation ( 
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Hypoxic cultures show an increase in lipid peroxidation compared to normoxic cultures. Lipid 
peroxidation in live cells was assessed by confocal fluorescence microscopy and the pixel density of 
each cell was measured. A549 cells were incubated for 30 minutes with 10M Lipid Peroxidation 
Sensor (a ratio metric dye). Scale bar, 50m. A high ratio (dark blue/green) indicates high levels of 
lipid peroxidation and a low ratio (light blue/magenta) indicates no lipid peroxidation (colour legend 
on the far right in the pictures). (A) Positive Control where lipid peroxidation was induced by treating 
the cells with Cumene Hydroperoxide. (B) Under basal conditions, normoxic cultures show no 
peroxidation whereas hypoxic cultures show constitutive lipid peroxidation (C). (D) Scatter plot of 
normalised pixel frequency against the ratio of fluorescence at 510 nm/590 nm (green/red) indicates 
a higher pixel density at the low ratio (peak at 0.1) in normoxic cultures compared to hypoxic cultures 
(peak at 0.5) and the positive control (peak at 1.0). 
 
 
D). A high frequency of pixels was observed at low 510/590 nm ratios (peak at 0.1) for the cells cultured 
under normoxic conditions which was in contrast to hypoxic cultures, where a high frequency of pixels 
was observed at higher ratios (peak at 0.5) while a positive control with lipid peroxidation induced with 
cumene hydroperoxide showed a high frequency of pixels with a peak 510/590 nm ratio of 1.0.  
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Hypoxic cultures show an increase in lipid peroxidation compared to normoxic cultures. Lipid 
peroxidation in live cells was assessed by confocal fluorescence microscopy and the pixel density of 
each cell was measured. A549 cells were incubated for 30 minutes with 10M Lipid Peroxidation 
Sensor (a ratio metric dye). Scale bar, 50m. A high ratio (dark blue/green) indicates high levels of 
lipid peroxidation and a low ratio (light blue/magenta) indicates no lipid peroxidation (colour legend 
on the far right in the pictures). (A) Positive Control where lipid peroxidation was induced by treating 
the cells with Cumene Hydroperoxide. (B) Under basal conditions, normoxic cultures show no 
peroxidation whereas hypoxic cultures show constitutive lipid peroxidation (C). (D) Scatter plot of 
normalised pixel frequency against the ratio of fluorescence at 510 nm/590 nm (green/red) indicates 
a higher pixel density at the low ratio (peak at 0.1) in normoxic cultures compared to hypoxic cultures 
(peak at 0.5) and the positive control (peak at 1.0). 
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Hypoxic cultures show an increase in lipid peroxidation compared to normoxic cultures. Lipid 
peroxidation in live cells was assessed by confocal fluorescence microscopy and the pixel density of 
each cell was measured. A549 cells were incubated for 30 minutes with 10M Lipid Peroxidation 
Sensor (a ratio metric dye). Scale bar, 50m. A high ratio (dark blue/green) indicates high levels of 
lipid peroxidation and a low ratio (light blue/magenta) indicates no lipid peroxidation (colour legend 
on the far right in the pictures). (A) Positive Control where lipid peroxidation was induced by treating 
the cells with Cumene Hydroperoxide. (B) Under basal conditions, normoxic cultures show no 
peroxidation whereas hypoxic cultures show constitutive lipid peroxidation (C). (D) Scatter plot of 
normalised pixel frequency against the ratio of fluorescence at 510 nm/590 nm (green/red) indicates 
a higher pixel density at the low ratio (peak at 0.1) in normoxic cultures compared to hypoxic cultures 
(peak at 0.5) and the positive control (peak at 1.0). 
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Co-localisation of LPO and effect of hypoxia on Structural changes of Mitochondria 
Increased LPO partially overlapped with mitochondria but was also apparent in other cell 
compartments.  Visual inspection of the images of cells labelled with Mitotracker Deep Red, shows that 
there were no significant changes in the structure of mitochondria under hypoxia (Figure 4.1). 
Figure 4.1: Co-localisation of Lipid peroxidation using mitotracker and structure of mitochondria 
under hypoxia 
 
Imaging of mitochondria and co-localisation of lipid peroxidation was determined by confocal 
microscopy. Scale bar, 50m. A549 cells cultured under hypoxia (2% O2) and Normoxia (21% O2) 
were incubated for 30 minutes with 200nM MitoTracker (mitochondria probe) and 10M Lipid 
Peroxidation Sensor. (A) Positive Control where lipid peroxidation was induced by treating the cells 
with Cumene Hydroperoxide. (B) Cells cultured under normoxia (21% O2).  (C) Cells cultured under 
hypoxia (2% O2). No changes were observed in the structure of mitochondria and the merged images 
showed lipid peroxidation in punctuate structures throughout the cell with incomplete co-localisation 
with mitochondria. 
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Hypoxic cultures of A549 cells show decrease in cellular ROS compared to Normoxic 
cultures. 
The effect of hypoxia on total ROS was assessed using carboxy-H2DCFDA by confocal imaging. The 
cells cultured under normoxic conditions had a greater green fluorescence emission compared to 
hypoxic cultures as shown in   
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Figure 4.2 B and C. The integrated density of pixels slightly decreased in hypoxic cultures indicating 
decline in peroxide radicals (  
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Figure 4.2 D). As there was auto fluorescence observed in the cells treated with nuclei stain (Hoechst 
33342) only, it was treated as negative control and included in the analysis. 
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Figure 4.2: ROS production in A549 cells 
 
D 
 
 
Generation of ROS in live cells was assessed by confocal fluorescence 
microscopy. Scale bar, 50m. A549 cells cultured under hypoxia (2% O2) and 
Normoxia (21% O2) were stained with a fluorescent ROS indicator (green). (A) 
Positive control where the ROS production was induced by incubating the cells 
for 1hour with 100M of tert-butyl hydroperoxide (TBHP) before staining and 
imaging. (B) Cells cultured under normoxic conditions. (C) Cells cultured under 
hypoxic conditions. All the groups were also labelled with 1M of Hoechst (blue) 
to identify cell nuclei. (D) The average pixel intensity (IOD) of all cells in the 
green channel was measured. Error bars indicate standard deviation of the mean 
IOD for three biological replicates (n=3). The difference in ROS fluorescence 
between normoxia and hypoxia was significant (P<0.05, Students t-test).  
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Discussion 
Many studies in the past decade have demonstrated increased lipid peroxidation products from cancer 
cells and tissues in oxidative stress [28-34]. It is also well established that the tumour micro-
environment causes oxidative stress resulting in cell cytotoxicity and that cellular anti-oxidant defences 
are increased as a means of protection [35, 36].  
In this study there was an apparent decrease in total ROS in hypoxic cultures compared to the normoxic 
cultures, which is consistent with the reduction of ROS in hypoxia found previously [37, 38]. In 
particular Kim et al. demonstrated in a human lymphoma cell line that under hypoxia ROS was 
attenuated by the overexpression of PDHK1 – a HIF-1 target gene [37] and we found PDHK1 to be 
increased in expression in A549 cells in hypoxia (Chapter 3 of this thesis). PDHK1 inactivates pyruvate 
dehydrogenase, so increased PDHK1 activity therefore deprives the tricarboxylic acid (TCA) cycle of 
Acetyl-CoA and instead promotes the conversion of pyruvate to lactate. This further suggests that in 
our studies, A549 cells have intact mitochondria and hence hypoxia will induce a metabolic shift of 
pyruvate away from the TCA cycle.  
Cancer cells exhibit metabolic alterations of several critical nutrients and substrates, including 
metabolic reprogramming of both glucose and glutamine [39]. There is sufficient evidence that 
increased lipid production and beta-oxidation of fatty acids may be a vital secondary energy source – 
essential for cancer cell survival [40-46]. Studies by Metallo et al. using isotopic labelled glutamine 
demonstrated that several mammalian cancer cells (including A549 cells) cultured under hypoxia 
alternatively produce Acetyl Co-A via reductive carboxylation of glutamine-derived alpha-
ketoglutarate (-KG) (de-novo lipogenesis) in the cytosol [47, 48].  
Lipid peroxidation is a chain reaction initiated by the interaction of ROS to generate hydroxyl radical 
which in turn abstracts hydrogen atoms from unsaturated lipids to produce lipid hydroperoxides [49-
52]. A substantial increase in the oxidation of lipids was observed in hypoxia indicating that lipid 
hydroperoxide free-radical mediated damage was operative. Interestingly, there was no lipid 
peroxidation in normoxic cultures, despite the slight increase in total ROS, which seems inconsistent. 
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This may be due to the substantial availability of lipids (from lipogenesis) in the cells cultured in 
hypoxia which might lead to the initiation of the chain reaction (an autocatalytic cycle) that will 
propagate until the free radical chain is terminated (which could be challenging to control). Also, the 
presence of ROS under normoxic conditions may be due to the lesser amounts of active anti-oxidant 
defences and ROS scavengers such as NADPH but this requires further investigation.  
Conclusion 
Hypoxia regulates ROS to enhance cell survival and to protect the cell from apoptosis. Lipid 
peroxidation is significantly increased in hypoxic cultures demonstrating the presence of oxidative 
degradation caused by free-radicals. Hence, hypoxic culture conditions are likely to alter cell 
metabolism and possibly VOC output from cells. 
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Abstract 
Lung cancer is often diagnosed at an advanced stage when prognosis is poor. A non-invasive diagnostic 
test suitable for population screening is needed to enable early diagnosis and improved patient survival. 
Volatile organic compounds (VOCs) in exhaled breath have potential as diagnostics however 
confirmation of the metabolic origins and disease specificity of candidate markers is required. Cell 
culture metabolomics can identify disease biomarkers and their origins. To date VOC profiles from in 
vitro cultured cancer cells show little similarity to breath profiles from cancer patients. One reason for 
this maybe that in vivo, cancer cells experience hypoxia whereas in vitro cells are generally cultured in 
normoxic conditions. Since hypoxia is known to influence cell metabolism we hypothesize that cancer 
cells cultured under hypoxic conditions will produce VOCs more typical of those found in cancer 
breath. We present data from A549 lung cancer cells cultured in suspension under standard normoxic 
(21% oxygen) or hypoxic (2% oxygen) conditions. VOCs were collected using solid phase micro-
extraction, analysed by Gas Chromatography-Mass Spectrometry and identified using the NIST11 mass 
spectral library. Environmental and system contaminants were identified by analysing incubator air 
(both normoxic and hypoxic) and media-only controls and these compounds were removed from the 
analysis. Comparison of endogenous VOCs produced by A549 cells under hypoxic and normoxic 
conditions showed twelve VOCs unique to cells grown under hypoxic conditions including four 
methylated alkanes and four alkenes. These classes of compounds have been commonly reported on 
cancer breath. A further four VOCs including two methylated alcohols were unique to cells grown in 
normoxic conditions, and two ketones were common to both. This data suggests that hypoxic culture 
conditions influence VOC production and is consistent with our hypothesis that hypoxia produces VOC 
profiles more similar to the breath of lung cancer patients. These results hold promise for the discovery 
of new and the validation of current VOC markers of lung cancer.  
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Introduction 
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer related deaths 
worldwide [1]. The five-year survival rate for lung cancer is generally poor as the symptoms become 
apparent only once the disease is well advanced. Better patient outcomes can be achieved with early 
diagnosis of this disease. Breath analysis appears to be the most propitious approach to detect and 
identify biomarkers related to a specific ailment, many volatile organic compounds (VOCs) have been 
analysed to identify new biomarkers of lung cancer [2-28].  
Many compounds on breath have been proposed as potential markers of lung cancer [29, 30] but their 
clinical relevance is still unclear [28]. Validation of the disease relevance of new breath biomarkers will 
be assisted by an understanding of the metabolic origins of the marker. However, there is currently 
limited knowledge about the metabolic origins and biochemical pathways that produce breath 
biomarkers. In-vitro studies provide an opportunity to identify disease biomarkers and their origins, 
however, there are only slight resemblances between the VOC profiles from in-vitro studies compared 
to lung cancer breath. Of the 68 VOCs detected on lung cancer breath and in the headspace of cancer 
cells in culture, only 16 VOCs are common to both [31-35] 
Recent studies have established that in-vivo cancer cells experience hypoxia as a consequence of oxygen 
diffusion limits in the tissues, which has been measured to be around 150 m [36, 37] resulting in 
altered cell metabolism [38, 39]. This raises the possibility that cells cultured under controlled low 
oxygen conditions will produce a pattern of VOCs that may aid in mapping biochemical origins of 
breath VOCs (Thesis Chapter 1, Section 3). The present study fills a gap in the literature by better 
mimicking the in-vivo conditions and provides new insights into the effects of culture conditions on the 
VOC profile produced by lung cancer cells. 
To investigate our hypothesis that cancer cells cultured under hypoxic conditions will produce VOCs 
more typical of those found in cancer breath, we first established an experimental in-vitro model where 
the oxygen conditions could be regulated and the VOCs effectively extracted and compared with those 
VOCs extracted from uncontrolled oxygen conditions (air). This model is based on the observations 
that hypoxia, a common hallmark of all cancers, causes metabolic alterations and may provide a 
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metabolic switch from oxidative phosphorylation to aerobic glycolysis and a concomitant increase in 
lipid peroxidation (see chapter 4). 
Methods 
Sample Preparation 
After growing to sub confluence in plastic culture flasks (Interpath Services, Melbourne, Australia) 
A549 cells were seeded at 10 million cells per 50 ml into a conical flask fitted with a Teflon stopper 
with a glass insert, through which a coated fused silica fibre could be introduced for the extraction of 
volatiles. The flask was placed on a magnetic stirrer (HD Scientific, Australia) and exposed to normoxia 
(21% O2) and hypoxia (2% O2) at 370C for 24hrs. The VOCs extracted from headspace of cells were 
compared against the VOCs extracted from the headspace of media without cells (controls). The air 
from both incubators was tested to identify system and environmental contaminants. 
GCMS Analyses 
The methodology used is discussed in detailed in Chapter 2, Section 2.3.2 of this Thesis. Both automatic 
and manual peak integration were executed for all the TICs and the compounds were identified by 
spectral match with NIST 2011 spectral library and only those with greater than 95% spectral match 
were considered positive. Overlapping unresolved peaks were not included in the analysis. Compound 
identity was further confirmed by retention times and the mass spectral pattern of neat standards where 
available (n-pentane, 3-methyl hexane and 2-nonanone). The retention times were internally consistent 
for each VOC and with standards where these were available. Preliminary calibration was performed 
using 100 and 1000 ppm speciality mix of alkanes with C2-C6 carbon skeleton to ensure that the detector 
was linear. Furthermore, to determine and confirm the candidate compounds of interest, standard curves 
were performed using a mixture of n-pentane, 3-methyl hexane and 2-nonanone (Accustandard) at 
concentrations of 10,30,100, 300 and 1000 ppm. For each compound the regression was linear from 10 
to 300 ppm. LOD and LOQ were calculated from the linear regression using the formula LOD = 3 x 
SD/slope and LOQ = 10 x SD/slope where SD is the standard deviation of the Y-residuals. The standard 
mixtures were collected using 75 m CAR/PDMS fibre by solid-phase micro extraction and were 
loaded using the auto sampler (Shimadzu Scientific Instruments) and released by thermal desorption 
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onto the injection port of the GCMS. Due to unavailability of standards, the other compounds of interest 
were identified by ion-extraction method using GCMS software and the fragments and their ratios were 
defined using NIST spectral library. The experiment was repeated on at least three independent samples 
with control and environmental air sampled from both the incubators for each experiment.   
Results 
Hypoxia produces unique VOC profiles  
Comparison of endogenous VOCs produced by A549 cells under hypoxic and normoxic conditions 
showed twelve VOCs unique to cells grown under hypoxic conditions as shown in Table 5.1. Data 
shown are for three independent experiments, indicated as Replicate 1, 2 and 3 (Rep1, 2 and 3). 
Environmental and system contaminants were identified using media-only controls and were 
disregarded from the analysis (as listed in Appendix II). Pentane was observed along with four 
methylated alkanes – 3-methyl hexane, 3 - ethyl pentane, 2,3,4 - trimethyl decane and 3,6 - dimethyl 
undecane (Table 5.1). For 3-methyl hexane trace quantities close to the LOD (approximately 17 ppm) 
and below LOQ (<56 ppm) were detected in hypoxic A549 cultures. For 2 –nonanone, two replicates 
were below LOQ (<117 ppm), and the third was above LOQ with 127 ppm detected. Another four 
volatile compounds were identified as alkenes, namely 3,3-dimethyl-1-hexene, 2,5-dimethyl-2-hexene, 
3-methyl-2-heptene and 7-methyl-1-undecene. Finally, there were three other VOCs: an alcohol 3-
Penten-1-ol, (Z), a ketone identified as 2-Nonanone and a cycloalkane identified as 1,5-diethyl-2,3-
dimethyl cyclohexane. 
A further four VOCs including two methylated alcohols were unique to cells grown in normoxic 
conditions. There was minimal overlap of VOCs between normoxic and hypoxic conditions with two 
ketones identified, which were 1-Hepten-6-one and 2- methyl-3-Octanone. 
Of the VOCs identified from the headspace of cultures, seventy-nine VOCs were identified as 
environmental or system contaminants. Of them, fifty-nine VOCs, were found in the headspace of 
control cultures (media without cells). The remaining twenty VOCs were found either in the headspace 
of controls or incubator air and identified as environmental contaminants (see Appendix II of this 
Thesis).  
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Table 5.1: VOCs produced by Hypoxic cultures only 
Class Compound  
Retention 
time  CAS No. Structure  Rep 1 Rep 2 Rep 3 
Alkanes n-Pentane 
13.21 
109-66-0 
 754845 70144 400440 
Methylated 
Alkanes 
Hexane, 3-
methyl- 
24.17 
589-34-4   2029387 1043960 2125286 
  Pentane, 3-ethyl- 
27.29 
617-78-7 
  736698 293839 885762 
  
Decane, 2,3,4-
trimethyl- 
38.05 
62238-15-7   17928675 12982075 32579041 
  
Undecane, 3,6-
dimethyl- 
40.77 
17301-28-9 
  4481110 8071465 4982126 
Alkenes 
1-hexene, 3,3-
dimethyl- 
27.06 
3404-77-1   644980 318836 900285 
  
2-hexene, 2,5-
dimethyl- 
28.16 
3404-78-2 
 
642914 294658 691998 
  
2-heptene, 3-
methyl-  
28.3 
3404-75-9 
 
2090555  -  1626000 
  
1-undecene, 7-
methyl- 
38.23 
74630-42-5 
 
1654215 1340093 3134859 
Alcohol 3-penten-1-ol, (Z) 
23.37 
764-38-5 
 2417804 853465 2279754 
Ketone 2-nonanone 
38.97 
821-55-6   1474386 2615736 4812724 
Cyclo alkane 
1,5-diethyl-2,3-
dimethyl 
cyclohexane 
40.4 
74663-66-4   8030218 3352667 5728835 
Table of areas of VOCs only found in the headspace of A549 cells cultured under hypoxia (2% O2).  Data shown 
are representative of three independent experiments (n = 3) indicated as Rep 1, Rep 2, Rep 3 in the table.  
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Discussion  
In-vitro studies versus Breath Analysis 
This study identified substantial differences between the VOC profiles from A549 cells cultured under 
normoxic and hypoxic conditions. The cells cultured under hypoxic conditions in particular produced a 
unique VOC profile consisting of 12 compounds that were not identified in normoxic cultures. These 
were mostly branched hydrocarbons along with a smaller number of alkenes, ketones, alcohols and a 
cycloalkane.  
n-Pentane and branched hydrocarbons are of particular interest.  
Firstly, pentane has been implicated as a volatile product of peroxidation of n-6 PUFAs [40-42], hence 
considered as an endogenous compound.  Pentane has been related to oxidative stress and bronchial 
asthma [43-46]. Recent studies by Kischkel et al. analysed the VOCs from cancer patients undergoing 
lung resection and demonstrated a significant decrease in exhaled concentrations of pentane after 
surgery [47]. This is a significant finding as this compound was only found in the headspace of cells 
cultured under hypoxia but not in the cells cultured under normoxia.  
Another significant finding is that the compounds belonging to the class of branched hydrocarbons were 
observed – 3-methyl hexane, 3 - ethyl pentane, 2,3,4 - trimethyl decane and 3,6 - dimethyl undecane. 
Of these compounds, 3-methyl hexane has been found associated with chronic liver disease [48], 
cholangiocarcinoma [49], and in lung cancer breath [43, 44]. Several of the VOCs from the hypoxic 
cultures have previously been reported as end-products of lipid peroxidation triggered by reactive 
oxygen species (ROS) and oxidative stress [50-52]. These results further support the idea that increased 
lipid peroxidation associated with hypoxia contributes to distinct VOC breath profiles in those with 
cancer and possibly other chronic conditions. Oxidative stress is a known fundamental mechanism 
associated with cancer growth and survival and the data shown here supports a role for hypoxia in 
promoting conditions favourable for lipid peroxidation and the release of methylated alkanes and 
alkenes.  
VOCs from cells cultured under controlled oxygen conditions versus VOCs from cells 
cultured using traditional culture conditions   
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Breath analysis has attracted attention in recent years and there are many studies that have detected and 
identified a variety of VOCs as potential biomarkers of cancer. A recent study by Kischkel et al. calls 
for the need for more rigorous standardized methods of sampling, analysis and data processing 
including the effects of environmental contaminants [28]. This was further supported by a review of the 
volatiles from the healthy human body by de Lacy Costello et al., that identified 872 metabolites related 
to smoking, food consumption and medication in breath [53]. Also, it emphasises the fact that the 
compounds are typically present not only in cancer patients but also in healthy controls and that the 
clinical relevance is yet to be established for any candidate VOCs reported so far. 
There were seventy-nine compounds identified as environmental and system contaminants in this study 
and these were present in all three independent experiments. Not considering these compounds in the 
analysis presented here was the most rigorous approach to avoiding reporting false positive compounds 
that do not derive from the lung cancer cells. It is noteworthy that a total of seventeen VOCs previously 
reported in the literature as produced by A549 cells were found as environmental and/or system 
contaminants in this study (Table 5.2). This is consistent with the need for minimising system 
contamination and the use of rigorous controls in in vitro studies of cancer metabolomics. 
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Table 5.2: Environmental and system contaminants 
Compounds are indicated in different coloured fonts to represent different groups as follows: Black = 
environmental and system contaminants in this study, Red = compounds found in this study in both controls 
and cells from both normoxic and hypoxic culture conditions but not incubator air, Blue = compounds that 
were found in this study only in controls from both the culture conditions and Green = compounds that were 
found in this study only in controls from normoxic conditions.  
Differences in sampling methods and analyses will lead to different VOCs as system contaminants. 
Furthermore, some system contaminants may also be derived independently from endogenous origins. 
For example, ethanol, an alcohol that has been reported as produced by the tumour tissues, released by 
the A549 cell lines and exhaled by cancer patients [31] also can originate from food, beverages and is 
produced by gut bacteria such as E coli [54, 56] and it is also used as a disinfectant for aseptic technique 
in many cell culture laboratories. Also, aromatic hydrocarbons such as Benzene, o-Xylene, p-Xylene, 
Styrene and Ethylbenzene are known by-products of gasoline, air pollutants and related to cigarette 
smoking [57-62], and ketones such as 2-butanone and 2-heptanone are reported to be produced by lactic 
No. Compound CAS No References 
1 Ethanol 64-17-5 [31, 54, 55] 
2 n-Butanal 123-72-8 [55] 
3 n-Pentanal 110-62-3 [55] 
4 2,4-Dimethyl-1-heptene 19549-87-2 [31, 54] 
5 Benzene 71-43-2 [55] 
6 o-Xylene 95-47-6 [57] 
7 p-Xylene 106-42-3 [55] 
8 Styrene 100-42-5 [55] 
9 Ethylbenzene 100-41-4 [55] 
10 Acetone 67-64-1 [31] 
11 2-Butanone 78-93-3 [55] 
12 Ethyl acetate 141-78-6 [55] 
13 2-methyl-1-pentene 763-29-1 [31, 54, 55] 
14 2-Ethyl Acrolein 922-63-4 [31] 
15 3-methyl butanal 590-86-3 [31, 54] 
16 n-Octane 111-65-9 [31, 54, 55] 
17 n-Heptane 142-82-5 [55] 
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acid bacteria [63]. The approach employed here whereby all system contaminants were eliminated from 
further study may have eliminated some VOCs that are relevant to disease, but it also ensures that the 
VOCs reported are in fact produced by the A549 cells, which may increase their utility as diagnostics. 
This study demonstrates that culture conditions influence the VOC profile of A549. Controlled oxygen 
conditions in particular appear to be necessary to alter the cell metabolism to produce VOCs similar to 
those found on breath.      
Conclusion 
The results of this study indicate that the culture conditions play a vital role on the VOC profile and 
controlled oxygen conditions are required to better mimic the in-vivo tumour environment. 
Additionally, two of the compounds expressed in hypoxic culture, n-Pentane and 3-methyl hexane, were 
previously reported to be present on breath of lung cancer patients. This approach may help in creation 
of a panel of compounds which could be useful as biomarkers of lung cancer.  
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Overview 
The initial hypothesis examined in this thesis is that hypoxia mediates changes in gene expression and 
altered cell metabolism in cancer cells which alters the VOCs produced, and may assist in identifying 
potential markers of the disease. This was tested with three studies. The first investigated the role of 
hypoxia on gene expression, identifying the ideal culture conditions to better mimic in-vivo conditions 
and where the metabolic switch from respiratory phenotype to glycolytic phenotype occurs. The second 
study examined free-radical production and lipid peroxidation in the hypoxic cultures, which may assist 
in identifying the possible biochemical origins of the VOCs. The third study assessed whether hypoxic 
cultures produced a distinctive VOC profile with the presence of an increased number of alkanes and 
methylated alkanes. 
Hypoxia mediates the metabolic switch from respiratory phenotype to glycolytic 
phenotype. 
The ideal oxygen percentage to culture the cells was determined Gene expression changes was analysed 
by qPCR on A549 cells cultured under various oxygen concentrations (1% O2, 2% O2 and 5% O2) 
compared to standard cell culture conditions (21% O2). This study showed statistically significant gene 
expression changes in the cells cultured under 2% O2 and 1% O2 and no significant changes were 
observed in the cells cultured under 5% O2. Also, hypoxia caused increased PDHK1 and GLUT1 
expression demonstrating a further shift towards glycolysis and away from OXHOS. These findings are 
consistent with other studies [1-3].  
Hypoxia increases Lipid Peroxidation    
The first stage of this study investigated the effect of hypoxia on auto-oxidation of lipids including co-
localisation of peroxidation and the structure of mitochondria in A549 cells. It was hypothesised that 
hypoxia would result in an increase in oxidative degradation of lipids mainly localised to mitochondria. 
However, the data obtained shows that there is a significant increase in lipid peroxidation in hypoxic 
cultures that does not correspond to just mitochondria. Additionally, there were no visual significant 
changes in the structure of mitochondria in hypoxic cultures. This data is consistent with A549 cells 
having functional mitochondria in hypoxia. 
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Furthermore, the second stage of this study investigated the generation of ROS in A549 cells under 
hypoxia. The data obtained shows decreased ROS in hypoxic cultures of A549 compared to normoxic 
controls which is consistent with the reduction of ROS in hypoxia found previously by two other studies 
[1, 2]. In particular, the former study demonstrated that hypoxia ROS is attenuated by the 
overexpression of PDHK1 – a HIF target gene [1] and we found PDHK1 to be increased in expression 
in hypoxic cultures of A549. Additionally, there is evidence that there is altered lipid metabolism in 
various cancers in-vitro which may be a vital secondary energy source [4-8]. Wise et al. demonstrated 
altered citrate production in hypoxic cultures of glioblastoma cells [9]. Reduced ROS in hypoxic 
cultures may be due to the increase antioxidant defences or ROS scavengers such as NADPH that are 
produced to enhance cell survival. However, this needs further elucidation.    
Hypoxia causes altered cell metabolism which may influence the VOCs produced by the 
cancer cells. 
The third and final study demonstrated the influence of hypoxia on the VOC profile in A549 cells. Since 
altered cell metabolism was observed under hypoxia, we hypothesised that hypoxic cultures will 
produce VOCs more typical of those found in cancer breath. The data obtained shows a unique VOC 
profile of hypoxic cultures with 12 VOCs produced only by A549 cells in hypoxic conditions. These 
consisted mostly of branched hydrocarbons along with a smaller number of alkenes, ketones, alcohols 
and a cycloalkane.  Of these, n-pentane and branched hydrocarbons are of particular interest as n-
pentane has been identified as a volatile product of peroxidation of n-6 PUFAS [10-12]. Additionally, 
it was found in breath of patients with bronchial asthma [13] and breath of lung cancer patients [14, 15]. 
This finding further supports the outcome of the second study of this thesis that there is increased LPO 
under hypoxic conditions.  
Detection of the branched hydrocarbons (3-methyl hexane, 2,3,4 - trimethyl decane, 3-ethylpentane and 
3,6 - dimethyl undecane) in only hypoxic cultures was an important finding. Of them, 3-methyl hexane 
has been detected on cancer breath [14] and found significantly increased in the breath of children with 
chronic liver disease [16]. Also, it was found in the headspace of bile of patients with 
Cholangiocarcinoma [17].  
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It has been suggested by Vaupel et al. that the Warburg effect requires modification, that cancer cell 
metabolism is heterogeneous, and that the tumour microenvironment influences oxygen availability and 
that this contributes to glycolysis to lactate in tumours [18]. The data presented here are consistent with 
the view that A549 have intact mitochondria (Chapter 5 of this thesis), that hypoxia causes increased 
anaerobic metabolism associated with increased PDHK1 and GLUT1 expression (therefore HIF 1 
activation), which results in a shift in cell metabolism as shown by changes in the VOCs being produced.  
To identify the candidate VOCs obtained from cancer metabolomics studies as biomarkers, they have 
to be validated by breath analysis of the patients with cancer and healthy controls. To test whether or 
not the unique VOCs produced by the hypoxic cultures are present on lung cancer breath, an interim 
study involving the collection of breath from patients diagnosed with lung cancer and healthy controls 
(age and sex matched) is in progress. Breath is collected in 100 ml glass sampling tube and VOCs 
harvested and detected as described in this thesis. This project was approved by the Federation 
University Human Ethics Committee with the project number A15-180.  
The preliminary results of this study (Myers MA, personal communication) are shown here (Table 6.1) 
with five cancer patients and five healthy controls matched for age and sex. Consistent with a previous 
study (Phillips et al.) 3-methyl hexane [14] was observed in the breath of two cancer patients, and 2,3-
butanedione [19] was found on breath of four cancer patients. Both these compounds were not detected 
in the breath of healthy controls, while n-Pentane was detected in breath of one cancer patient and one 
healthy control. While the breath study outlined here is in its early stages and the sample size is currently 
insufficient for conclusions to be drawn, it does confirm that 3-methyl hexane can be detected on breath 
from lung cancer patients, so providing support for the use of in vitro cell culture under low oxygen for 
the discovery of potential biomarkers.  
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Diagnosis Mean 
Age 
(Years) 
Age 
range 
(Years) 
Gender Number (n) 3-methyl 
hexane 
n-
pentane 
2,3-
butanedione 
Lung cancer 64.4 43 to 85 3M 2F 5 2 1 4 
Healthy 
control 
59.8 44 to 85 3M 2F 5 0 1 0 
Table 6.1: Preliminary results of the interim study 
VOCs found on the breath of the patients diagnosed with lung cancer vs healthy controls (M – Male and F – 
Female). 
 
Conclusions 
This thesis demonstrates the role of hypoxia in the regulation of the cell metabolism and VOC 
production in A549 cells. This data is consistent with our hypothesis that hypoxic cultures of A549 cells 
produce a unique VOC profile characteristic of cancer cells as they closely mimic the conditions of 
cancer cell growth in vivo. The relevance of this work to cancer diagnosis is outlined in Figure 6.1, 
which describes how micro physiological conditions in tumours could lead to altered cancer cell 
metabolism and VOC breath profiles. 
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Figure 6.1: Influence of hypoxia on VOC output 
Micro-physiological conditions effect cell metabolism and may influence the VOCs 
produced in the breath, which may be useful for identifying markers for early diagnosis in 
lung cancer patients. 
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Future Directions 
Cancer cell metabolomics in hypoxic conditions provides a great opportunity to test hypotheses around 
VOC profiles from different cancers and biochemical factors that may influence their production. Also, 
the cell culture metabolomics approach can be extended to other cancer cell lines such as liver cancer 
(HepG2), breast cancer (MCF7) to produce unique VOC profiles. This might provide more insight to 
the biochemical origins of VOCs. Another area for further exploration is antioxidant defence in cancer 
cells. It is hypothesised that under hypoxia, the antioxidant defences may be increased in cancer cells 
to protect the cell from cytotoxic effects of ROS and to aid cell survival and proliferation. This could 
be elucidated further by the treatment of A549 cells with inhibitors of SOD and/or NOX and measuring 
levels of ROS activity. Also, the above approach could help in clarification of the role of mitochondria 
in ROS production and the subcellular origins of VOCs. Furthermore, the breath of the cancer patients 
can be collected before and after the surgery (for example lung resection) or other treatment and 
analysed which may perhaps be useful to test the link between the cancer burden and its influence on 
VOC output, specifically related to LPO products, which could be implicated in disease prognosis. 
Cell culture metabolomics under low oxygen may be exploited to discover biomarkers for the design 
of screening tests for early diagnosis of diseases such as Ischemia, Chronic Obstructive Pulmonary 
Disorder (COPD) and Diabetes. Technological advances are today making breath analysis as a point of 
care diagnostic possible. Identifying the most specific and useful disease markers should be aided by 
such insights in to how these VOCs are produced. These tests in the future will be a non-invasive method 
for cancer diagnosis and monitoring of disease progression.   
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Appendix I 
 
A  B 
 
C 
 
D 
 
E 
 
 Figure Legend 
 
Figure 1: mRNA expression of the 
hypoxia associated genes relative to the 
housekeeping gene, EEF2 in A549 cells 
cultured under various oxygen 
concentrations compared to their 
controls. Relative expression of 
GLUT1, PDHK1, LDH-A, mTOR and 
PKM2 mRNA to EEF2 (A-E). Error 
bars indicate the SD from three 
independent biological samples.  
*P < 0.05, **P < 0.005. 
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Appendix II 
ENVIRONMENTAL AND SYSTEM CONTAMINANTS 
CLASS NO. COMPOUNDS CAS. NO. 
ALKANES (ACYCLIC, 
METHYLATED AND 
SUBSTITUTED) 
1 n-Hexane 110-54-3 
2 Tetradecane 629-59-4 
  3 Octane, 4-methyl- 2216-34-4 
  4 Decane, 3,6-dimethyl- 17312-53-7 
  5 Decane, 1-iodo- 2050-77-3 
  6 Undecane 1120-21-4 
  7 Dodecane, 2-methyl- 1560-97-0 
  8 Dodecane, 4,6-dimethyl- 61141-72-8 
  9 Pentadecane, 7-methyl-  6165-40-8 
  10 Tetracontane, 3,5,24-trimethyl- 55162-61-3 
  11 Hexacosane 630-01-3 
  12 1-Chloroeicosane 42217-02-7 
 13 Heptane, 4-methyl- 589-53-7 
 14 Pentane, 2,3,4-trimethyl- 565-75-3 
 15 Trichloromethane  67-66-3 
 16 Octane  111-65-9 
 17 n-Heptane 142-82-5 
 18 Heptane, 2,5,5-trimethyl- 1189-99-7 
 19 Pentadecane 629-62-9 
ALKENES       
  20 2-Heptene  592-77-8 
  21 2-Octene, (Z)-  7642-04-8  
  22 2,4-Dimethyl-1-heptene 19549-87-2 
 23 1-Pentene, 2-methyl- 763-29-1 
 24 2-Octene 111-67-1 
 25 Cyclohexene 110-83-8 
 26 3-Octene, (Z)- 14850-22-7 
 27 1-Octene, 3,7-dimethyl- 4/01/4894 
ALCOHOLS        
  28 Ethanol 64-17-5 
  29 1-Butanol  71-36-3 
  30 
1-Hexanol, 5-methyl-2-(1-
methylethyl)- 2051-33-4 
  31 3-Heptanol 589-82-2 
  32 Cyclohexanol 108-93-0 
  33 1-Dodecanol, 2-hexyl- 110225-00-8 
 34 2-Nonen-1-ol 22104-79-6 
ALDEHYDES       
  35 Acetaldehyde 75-07-0 
  36 Butanal 123-72-8 
  37 Pentanal 110-62-3 
  38 Hexanal 66-25-1 
  39 Octanal 124-13-0 
 40 Butanal, 3-methyl- 590-86-3 
 41 2-Ethylacrolein  922-63-4 
KETONES      
  42 Acetone 67-64-1 
  43 2-Butanone 78-93-3 
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ENVIRONMENTAL AND SYSTEM CONTAMINANTS 
CLASS NO. COMPOUNDS CAS. NO. 
  44 2-Hexanone 591-78-6 
  45 3-Heptanone 106-35-4 
  46 2-Heptanone 110-43-0 
  47 2-Octanone 111-13-7 
  48 Methyl Isobutyl Ketone 108-10-1 
  49 2,3-Butanedione 431-03-8 
 50 4-Octanone 589-63-9 
AROMATICS 
COMPOUNDS      
  51 Benzene 71-43-2 
  52 Toluene 108-88-3 
  53 Ethylbenzene 100-41-4 
  54 Benzene, 1-ethyl-3-methyl- 620-14-4 
  55 Benzene, 1-ethyl-4-methyl- 622-96-8 
  56 Benzene, 1-ethyl-2-methyl- 611-14-3 
  57 Mesitylene 108-67-8 
  58 
Benzene, 1,3-bis(1,1-
dimethylethyl)- 1014-60-4 
  59 Benzene, 1,4-diethyl- 105-05-5 
  60 o-Cymene 527-84-4 
  61 p-Cymene 99-87-6 
  62 Styrene 100-42-5 
  63 o-Xylene 95-47-6 
  64 Phenol 108-95-2 
  65 Acetophenone 98-86-2 
  66 Benzaldehyde 100-52-7 
HETEROCYCLIC 
COMPOUNDS       
  67 2,4-Dimethylfuran 3710-43-8 
  68 
Tricyclo[3.1.0.0(2,4)]hex-3-ene-3-
carbonitrile NA 
  69 Hexanamide, N-methallyl- NA 
  70 Benzofuran 271-89-6 
  71 Cyclotrisiloxane, hexamethyl-  541-05-9 
ESTERS       
  72 
2-Furancarboxylic acid, 2-
tetrahydrofurylmethyl ester NA 
  73 
Sulfurous acid, cyclohexylmethyl 
hexadecyl ester NA 
  74 
Trifluoroacetic acid,n-tridecyl 
ester NA 
  75 Ethyl Acetate 141-78-6 
 76 
Formic acid, cis-4-
methylcyclohexyl ester NA 
CYCLIC 
COMPOUNDS    
 77 
Cyclohexane, 1-ethyl-1,3-
dimethyl-, cis-  NA 
 78 Bicyclo[4.2.0]octa-1,3,5-triene   694-87-1 
OTHERS    
 79 Hydroperoxide, pentyl 74-80-6 
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Appendix III 
 
VOCs from A549 cells under Normoxia  
VOCs from A549 cells under Hypoxia 
